OA19256A - Anti-Viral Compounds. - Google Patents
Anti-Viral Compounds. Download PDFInfo
- Publication number
- OA19256A OA19256A OA1201400136 OA19256A OA 19256 A OA19256 A OA 19256A OA 1201400136 OA1201400136 OA 1201400136 OA 19256 A OA19256 A OA 19256A
- Authority
- OA
- OAPI
- Prior art keywords
- virus
- compound
- cor
- independently
- cells
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 167
- 230000000840 anti-viral Effects 0.000 title description 44
- 208000001756 Virus Disease Diseases 0.000 claims abstract description 16
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 10
- 206010047461 Viral infection Diseases 0.000 claims abstract description 10
- 230000000051 modifying Effects 0.000 claims abstract description 10
- 230000017613 viral reproduction Effects 0.000 claims abstract description 10
- 210000004027 cells Anatomy 0.000 claims description 113
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 112
- 241000700605 Viruses Species 0.000 claims description 72
- 229910052801 chlorine Inorganic materials 0.000 claims description 55
- 229910052794 bromium Inorganic materials 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 37
- 229910052731 fluorine Inorganic materials 0.000 claims description 32
- 229910004755 ORb Inorganic materials 0.000 claims description 27
- 241000282414 Homo sapiens Species 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 229960005486 vaccines Drugs 0.000 claims description 24
- 229910052740 iodine Inorganic materials 0.000 claims description 22
- 241000712461 unidentified influenza virus Species 0.000 claims description 19
- 241000710886 West Nile virus Species 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 17
- 230000000240 adjuvant Effects 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 12
- 230000001225 therapeutic Effects 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 8
- 241000725619 Dengue virus Species 0.000 claims description 7
- 230000015788 innate immune response Effects 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000003107 substituted aryl group Chemical group 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 241000961587 Secoviridae Species 0.000 claims description 6
- 241000178320 Alfuy virus Species 0.000 claims description 5
- 241001536481 Banzi virus Species 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 241000991587 Enterovirus C Species 0.000 claims description 5
- 241000711549 Hepacivirus C Species 0.000 claims description 5
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 5
- 241000178323 Kokobera virus Species 0.000 claims description 5
- 241000710912 Kunjin virus Species 0.000 claims description 5
- 241001466978 Kyasanur forest disease virus Species 0.000 claims description 5
- 241000710769 Louping ill virus Species 0.000 claims description 5
- 241000712079 Measles morbillivirus Species 0.000 claims description 5
- 241000710884 Powassan virus Species 0.000 claims description 5
- 241000907332 Rocio virus Species 0.000 claims description 5
- 241000315672 SARS coronavirus Species 0.000 claims description 5
- 241000710888 St. Louis encephalitis virus Species 0.000 claims description 5
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 5
- 241000710772 Yellow fever virus Species 0.000 claims description 5
- 201000008286 diarrhea Diseases 0.000 claims description 5
- 229940051021 yellow-fever virus Drugs 0.000 claims description 5
- 229910004664 ORa Inorganic materials 0.000 claims description 4
- 241000961634 Alphaflexiviridae Species 0.000 claims description 3
- 241000712892 Arenaviridae Species 0.000 claims description 3
- 241001533362 Astroviridae Species 0.000 claims description 3
- 241000702628 Birnaviridae Species 0.000 claims description 3
- 241001533462 Bromoviridae Species 0.000 claims description 3
- 241000714198 Caliciviridae Species 0.000 claims description 3
- 241000973027 Closteroviridae Species 0.000 claims description 3
- 241000702221 Cystoviridae Species 0.000 claims description 3
- 241000710781 Flaviviridae Species 0.000 claims description 3
- 241000700739 Hepadnaviridae Species 0.000 claims description 3
- 241001112094 Hepevirus Species 0.000 claims description 3
- 241000700586 Herpesviridae Species 0.000 claims description 3
- 241000714210 Leviviridae Species 0.000 claims description 3
- 241000253097 Luteoviridae Species 0.000 claims description 3
- 241000711513 Mononegavirales Species 0.000 claims description 3
- 229910003813 NRa Inorganic materials 0.000 claims description 3
- 241001292005 Nidovirales Species 0.000 claims description 3
- 241000723741 Nodaviridae Species 0.000 claims description 3
- 241000712464 Orthomyxoviridae Species 0.000 claims description 3
- 241001631646 Papillomaviridae Species 0.000 claims description 3
- 241000711504 Paramyxoviridae Species 0.000 claims description 3
- 241000150350 Peribunyaviridae Species 0.000 claims description 3
- 241001492235 Picobirnavirus Species 0.000 claims description 3
- 241000709664 Picornaviridae Species 0.000 claims description 3
- 241001533393 Potyviridae Species 0.000 claims description 3
- 241000702247 Reoviridae Species 0.000 claims description 3
- 241000712907 Retroviridae Species 0.000 claims description 3
- 229910003667 SRa Inorganic materials 0.000 claims description 3
- 241000724318 Tenuivirus Species 0.000 claims description 3
- 241000710924 Togaviridae Species 0.000 claims description 3
- 241001533336 Tombusviridae Species 0.000 claims description 3
- 241000710915 Totiviridae Species 0.000 claims description 3
- 241001059845 Tymoviridae Species 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 92
- 101700064525 DDX58 Proteins 0.000 abstract description 22
- 102100013885 DDX58 Human genes 0.000 abstract description 22
- 230000037361 pathway Effects 0.000 abstract description 9
- 229920000160 (ribonucleotides)n+m Polymers 0.000 abstract description 8
- -1 CsHn Chemical group 0.000 description 102
- 201000009910 diseases by infectious agent Diseases 0.000 description 40
- 239000003814 drug Substances 0.000 description 39
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 33
- 230000000670 limiting Effects 0.000 description 29
- 230000003612 virological Effects 0.000 description 28
- 229910006074 SO2NH2 Inorganic materials 0.000 description 26
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 24
- 229940079593 drugs Drugs 0.000 description 23
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 23
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 20
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 20
- 125000003118 aryl group Chemical group 0.000 description 18
- 230000001965 increased Effects 0.000 description 18
- 210000004681 Ovum Anatomy 0.000 description 17
- 125000004429 atoms Chemical group 0.000 description 17
- 238000004166 bioassay Methods 0.000 description 17
- 125000000304 alkynyl group Chemical group 0.000 description 16
- 102000004965 antibodies Human genes 0.000 description 16
- 108090001123 antibodies Proteins 0.000 description 16
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 231100000673 dose–response relationship Toxicity 0.000 description 15
- 125000000524 functional group Chemical group 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 230000035492 administration Effects 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 102000038129 antigens Human genes 0.000 description 14
- 108091007172 antigens Proteins 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 125000004122 cyclic group Chemical group 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 102000007578 Interferon Regulatory Factor-3 Human genes 0.000 description 12
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 12
- 241000724205 Rice stripe tenuivirus Species 0.000 description 12
- 125000004432 carbon atoms Chemical group C* 0.000 description 11
- 230000000275 pharmacokinetic Effects 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 10
- 206010022000 Influenza Diseases 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 Blood Anatomy 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 208000006572 Human Influenza Diseases 0.000 description 8
- 102100010001 IFIT2 Human genes 0.000 description 8
- 101700021842 IFIT2 Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000005556 structure-activity relationship Methods 0.000 description 8
- 125000001544 thienyl group Chemical group 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 200000000003 influenza A Diseases 0.000 description 7
- 230000008506 pathogenesis Effects 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- GXAFMKJFWWBYNW-OWHBQTKESA-N 2-[3-[(1R)-1-[(2S)-1-[(2S)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC2CC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GXAFMKJFWWBYNW-OWHBQTKESA-N 0.000 description 6
- 102000004851 Immunoglobulin G Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 230000036882 MTD Effects 0.000 description 6
- 229960000329 Ribavirin Drugs 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 125000003282 alkyl amino group Chemical group 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 231100000730 tolerability Toxicity 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 208000005176 Hepatitis C Diseases 0.000 description 5
- 101700018430 MAVS Proteins 0.000 description 5
- 102000016350 Viral Proteins Human genes 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 5
- 230000001413 cellular Effects 0.000 description 5
- 238000010192 crystallographic characterization Methods 0.000 description 5
- 241001493065 dsRNA viruses Species 0.000 description 5
- 230000002708 enhancing Effects 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 210000000056 organs Anatomy 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 241000710815 Dengue virus 2 Species 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
- 108060001084 Luciferase family Proteins 0.000 description 4
- 102100003102 MAVS Human genes 0.000 description 4
- 210000002540 Macrophages Anatomy 0.000 description 4
- 101700016688 OAS1 Proteins 0.000 description 4
- 102100010861 OAS1 Human genes 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 210000003501 Vero Cells Anatomy 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 125000004442 acylamino group Chemical group 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 4
- 125000005110 aryl thio group Chemical group 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 230000000903 blocking Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 101710041676 cysl-1 Proteins 0.000 description 4
- 230000001086 cytosolic Effects 0.000 description 4
- 230000000534 elicitor Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000002458 infectious Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 150000002611 lead compounds Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 150000003462 sulfoxides Chemical class 0.000 description 4
- 230000002110 toxicologic Effects 0.000 description 4
- 101710027066 ALB Proteins 0.000 description 3
- 210000004556 Brain Anatomy 0.000 description 3
- 229920002676 Complementary DNA Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000004443 Dendritic Cells Anatomy 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229940014259 Gelatin Drugs 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 231100000750 In vitro toxicology Toxicity 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 231100000070 MTS assay Toxicity 0.000 description 3
- 238000000719 MTS assay Methods 0.000 description 3
- 241000711408 Murine respirovirus Species 0.000 description 3
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 208000009341 RNA Virus Infections Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229940042406 direct acting antivirals Neuraminidase inhibitors Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 230000003870 intestinal permeability Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000002911 sialidase inhibitor Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 102000003995 transcription factors Human genes 0.000 description 3
- 108090000464 transcription factors Proteins 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000005951 type IV hypersensitivity Effects 0.000 description 3
- 238000004450 types of analysis Methods 0.000 description 3
- ARAIBEBZBOPLMB-UFGQHTETSA-N (2R,3R,4S)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N 3-Mercaptopropane-1,2-diol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 101700033661 ACTB Proteins 0.000 description 2
- 102100011550 ACTB Human genes 0.000 description 2
- 101710032514 ACTI Proteins 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 101710036216 ATEG_03556 Proteins 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 229960003805 Amantadine Drugs 0.000 description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N Arabitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 102100008428 CCL2 Human genes 0.000 description 2
- 101700006000 CCL2 Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- ZVTDLPBHTSMEJZ-UPZRXNBOSA-N DANOPREVIR Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCC[C@H](C(N1C[C@@H](C[C@H]1C(=O)N2)OC(=O)N1CC2=C(F)C=CC=C2C1)=O)NC(=O)OC(C)(C)C)NS(=O)(=O)C1CC1 ZVTDLPBHTSMEJZ-UPZRXNBOSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 210000000624 Ear Auricle Anatomy 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 210000002216 Heart Anatomy 0.000 description 2
- 208000006454 Hepatitis Diseases 0.000 description 2
- 229960002885 Histidine Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100018939 IFIT1 Human genes 0.000 description 2
- 101700084153 IFIT1 Proteins 0.000 description 2
- 101700070228 IFN Proteins 0.000 description 2
- 101700066403 IFNA1 Proteins 0.000 description 2
- 101700023446 IFNT Proteins 0.000 description 2
- 101710004164 ISYNA1 Proteins 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 210000001165 Lymph Nodes Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- YQNQNVDNTFHQSW-UHFFFAOYSA-N Nitazoxanide Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 2
- 101800001014 Non-structural protein 5A Proteins 0.000 description 2
- 101710003000 ORF1/ORF2 Proteins 0.000 description 2
- 229960003752 Oseltamivir Drugs 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N Oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 229940092253 Ovalbumin Drugs 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 101710043203 P23p89 Proteins 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- 230000036660 Plasma protein binding Effects 0.000 description 2
- 101700030467 Pol Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N Taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000007510 West Nile Fever Diseases 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 Xylitol Drugs 0.000 description 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 2
- 229960001028 Zanamivir Drugs 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 201000002531 karyomegalic interstitial nephritis Diseases 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrugs Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001718 repressive Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 101710004466 rgy Proteins 0.000 description 2
- 101710030364 rgy1 Proteins 0.000 description 2
- 101710030359 rgy2 Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- 229950006081 taribavirin Drugs 0.000 description 2
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 2
- LKHDXIBHVSGUHN-UHFFFAOYSA-N thiadiazole 1,1-dioxide Chemical compound O=S1(=O)C=CN=N1 LKHDXIBHVSGUHN-UHFFFAOYSA-N 0.000 description 2
- XWMXMWHHTIEXRE-UHFFFAOYSA-N thiadiazole 1-oxide Chemical compound O=S1C=CN=N1 XWMXMWHHTIEXRE-UHFFFAOYSA-N 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- RNEACARJKXYVND-KQGZCTBQSA-N (2R)-2-[[(5Z)-5-[(5-ethylfuran-2-yl)methylidene]-4-oxo-1,3-thiazol-2-yl]amino]-2-(4-fluorophenyl)acetic acid Chemical compound O1C(CC)=CC=C1\C=C/1C(=O)N=C(N[C@@H](C(O)=O)C=2C=CC(F)=CC=2)S\1 RNEACARJKXYVND-KQGZCTBQSA-N 0.000 description 1
- CATMPQFFVNKDEY-YPMHNXCESA-N (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid Chemical compound C1=CC=C2C(C[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(O)=O)=CNC2=C1 CATMPQFFVNKDEY-YPMHNXCESA-N 0.000 description 1
- MHFMTUBUVQZIRE-WINRQGAFSA-N (2S,4R)-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-3,3-dimethyl-2-(2-oxo-2-piperidin-1-ylethyl)butanoyl]-4-(7-methoxy-2-phenylquinolin-4-yl)oxypyrrolidine-2-carboxamide Chemical compound C([C@H](C(=O)N1[C@@H](C[C@H](C1)OC=1C2=CC=C(C=C2N=C(C=1)C=1C=CC=CC=1)OC)C(=O)N[C@]1([C@@H](C1)C=C)C(=O)NS(=O)(=O)C1CC1)C(C)(C)C)C(=O)N1CCCCC1 MHFMTUBUVQZIRE-WINRQGAFSA-N 0.000 description 1
- AQHMBDAHQGYLIU-XNFHFXFQSA-N (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10, Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O AQHMBDAHQGYLIU-XNFHFXFQSA-N 0.000 description 1
- PPDBOQMNKNNODG-ZROIWOOFSA-N (5Z)-5-[(4-chlorophenyl)methylidene]-2,2-dimethyl-1-(1,2,4-triazol-1-ylmethyl)cyclopentan-1-ol Chemical compound C1=NC=NN1CC1(O)C(C)(C)CC\C1=C\C1=CC=C(Cl)C=C1 PPDBOQMNKNNODG-ZROIWOOFSA-N 0.000 description 1
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- YFXGICNMLCGLHJ-RSKRLRQZSA-N 2,2-dimethylpropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate Chemical compound C1=CC=C2C(OP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)OC[C@H]3O[C@H]([C@]([C@@H]3O)(C)O)N3C=4N=C(N)N=C(C=4N=C3)OC)=CC=CC2=C1 YFXGICNMLCGLHJ-RSKRLRQZSA-N 0.000 description 1
- HTCSFFGLRQDZDE-UHFFFAOYSA-N 2-azaniumyl-2-phenylpropanoate Chemical compound OC(=O)C(N)(C)C1=CC=CC=C1 HTCSFFGLRQDZDE-UHFFFAOYSA-N 0.000 description 1
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-Hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 1
- AQIXEPGDORPWBJ-UHFFFAOYSA-N 3-Pentanol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 1
- ROSNVSQTEGHUKU-UHFFFAOYSA-N 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)CC1(C(=O)NO)CCOCC1 ROSNVSQTEGHUKU-UHFFFAOYSA-N 0.000 description 1
- WPMJNLCLKAKMLA-UHFFFAOYSA-N 5-(3,3-dimethylbut-1-ynyl)-3-[(4-hydroxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylic acid Chemical compound C1CC(C)CCC1C(=O)N(C1=C(SC(=C1)C#CC(C)(C)C)C(O)=O)C1CCC(O)CC1 WPMJNLCLKAKMLA-UHFFFAOYSA-N 0.000 description 1
- 108060000679 ATG12 Proteins 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229960003767 Alanine Drugs 0.000 description 1
- 229940060516 Alferon N Drugs 0.000 description 1
- 229940054685 Alinia Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K Aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 241000714197 Avian myeloblastosis-associated virus Species 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 229950007843 Bavituximab Drugs 0.000 description 1
- 229960002233 Benzalkonium Bromide Drugs 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 102100016449 CCL5 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- CJXAEXPPLWQRFR-UHFFFAOYSA-N Clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 description 1
- 229950002020 Clemizole Drugs 0.000 description 1
- 230000037242 Cmax Effects 0.000 description 1
- 229940055354 Copegus Drugs 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108020004461 Double-Stranded RNA Proteins 0.000 description 1
- 101700057458 Drice Proteins 0.000 description 1
- 102000033180 ERVK-6 Human genes 0.000 description 1
- 101710038044 ERVK-6 Proteins 0.000 description 1
- 101710027967 ERVW-1 Proteins 0.000 description 1
- 229940009714 Erythritol Drugs 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 241000272190 Falco peregrinus Species 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N Favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N Galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 229960002449 Glycine Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 230000036297 Hepatic clearance Effects 0.000 description 1
- 208000002672 Hepatitis B Diseases 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 1
- YEPBUHWNLNKZBW-FDVAVYTKSA-N IDX320 Chemical compound O=C([C@]12NC(=O)[C@H]3N(C(N(C)CCCC/C=C/[C@@H]1C2)=O)CC[C@@H](C3)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(F)(F)F)C)OC)NS(=O)(=O)C1(C)CC1 YEPBUHWNLNKZBW-FDVAVYTKSA-N 0.000 description 1
- 101700086956 IFNG Proteins 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 102000004090 Immunoglobulin Isotypes Human genes 0.000 description 1
- 108090000539 Immunoglobulin Isotypes Proteins 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 230000035708 Intrinsic clearance Effects 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 description 1
- 229950004244 Laninamivir Drugs 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N Lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- 229940087857 Lupron Drugs 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000036676 Maximum tolerable dose Effects 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 210000001853 Microsomes, Liver Anatomy 0.000 description 1
- 210000001700 Mitochondrial Membranes Anatomy 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N N'-amino-N-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- ICIJBYYMEBOTQP-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide;hydrochloride Chemical compound Cl.C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ICIJBYYMEBOTQP-UHFFFAOYSA-N 0.000 description 1
- 102100011700 NTPCR Human genes 0.000 description 1
- 108010075285 Nucleoside-Triphosphatase Proteins 0.000 description 1
- 229910004682 ON-OFF Inorganic materials 0.000 description 1
- 230000035536 Oral bioavailability Effects 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 102100012530 PPIA Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940002988 Pegasys Drugs 0.000 description 1
- 229940106366 Pegintron Drugs 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241001463913 Pinna Species 0.000 description 1
- 230000037289 Plasma half life Effects 0.000 description 1
- 230000037240 Plasma half-life Effects 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000004409 RNA helicases Human genes 0.000 description 1
- 230000025458 RNA interference Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 229940053146 Rebetol Drugs 0.000 description 1
- 229940061374 Relenza Drugs 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N Resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 Resiquimod Drugs 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N Ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FGHMGRXAHIXTBM-TWFJNEQDSA-N S-[2-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-(benzylamino)phosphoryl]oxyethyl] 3-hydroxy-2,2-dimethylpropanethioate Chemical compound C([C@@H]1[C@H]([C@@](C)(O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1)O)OP(=O)(OCCSC(=O)C(C)(CO)C)NCC1=CC=CC=C1 FGHMGRXAHIXTBM-TWFJNEQDSA-N 0.000 description 1
- 125000005631 S-sulfonamido group Chemical group 0.000 description 1
- 108010090287 SCY-635 Proteins 0.000 description 1
- 229940046307 SODIUM THIOGLYCOLATE Drugs 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 101710023234 Segment 5 Proteins 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- DEKOYVOWOVJMPM-RLHIPHHXSA-N Setrobuvir Chemical compound N1([C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(O)=C(C1=O)C=1NC2=CC=C(C=C2S(=O)(=O)N=1)NS(=O)(=O)C)CC1=CC=C(F)C=C1 DEKOYVOWOVJMPM-RLHIPHHXSA-N 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N Stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M Stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940061367 Tamiflu Drugs 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229940045136 Urea Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 229940045145 Uridine Drugs 0.000 description 1
- 101700028070 VPX Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229960003487 Xylose Drugs 0.000 description 1
- OQOQSRMIBLJVHE-UHFFFAOYSA-L [K+].[K+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O Chemical compound [K+].[K+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O OQOQSRMIBLJVHE-UHFFFAOYSA-L 0.000 description 1
- KNKDZWFHOIKECV-UHFFFAOYSA-L [K+].[K+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O Chemical compound [K+].[K+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O KNKDZWFHOIKECV-UHFFFAOYSA-L 0.000 description 1
- KYOYLUVYCHVYGC-BUOKYLHBSA-M [Na+].OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C([O-])=O Chemical compound [Na+].OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C([O-])=O KYOYLUVYCHVYGC-BUOKYLHBSA-M 0.000 description 1
- WGFMTHGYKYEDHF-UHFFFAOYSA-L [Na+].[Na+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O Chemical compound [Na+].[Na+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O WGFMTHGYKYEDHF-UHFFFAOYSA-L 0.000 description 1
- GZLGNNHEHXBCBI-UHFFFAOYSA-L [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O Chemical compound [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O GZLGNNHEHXBCBI-UHFFFAOYSA-L 0.000 description 1
- SILCDLWESNHZKB-UHFFFAOYSA-L [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 1
- JYXKLAOSCQDVIX-NFMYELBMSA-K [Na+].[Na+].[Na+].OC(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O Chemical compound [Na+].[Na+].[Na+].OC(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O JYXKLAOSCQDVIX-NFMYELBMSA-K 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000004062 acenaphthenyl group Chemical group C1(CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 102000035425 adaptor proteins Human genes 0.000 description 1
- 108091005736 adaptor proteins Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 125000005011 alkyl ether group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000001174 ascending Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 239000012523 bacterial endotoxin Substances 0.000 description 1
- 108010001114 bavituximab Proteins 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960000539 carbamide Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 125000003336 coronenyl group Chemical group C1(=CC2=CC=C3C=CC4=CC=C5C=CC6=CC=C1C1=C6C5=C4C3=C21)* 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 150000003999 cyclitols Chemical class 0.000 description 1
- 125000000582 cycloheptyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000000120 cytopathologic Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000741 diarrhetic Effects 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- OSIAURSWRZARKZ-UHFFFAOYSA-N dihydroxyphosphinothioylformic acid Chemical compound OC(=O)P(O)(O)=S OSIAURSWRZARKZ-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- MYSDBRXBYJKGLB-WOGKQDBSSA-L disodium;(E)-but-2-enedioate;(E)-but-2-enedioic acid Chemical compound [Na+].[Na+].OC(=O)\C=C\C(O)=O.[O-]C(=O)\C=C\C([O-])=O MYSDBRXBYJKGLB-WOGKQDBSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000003914 fluoranthenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC=C4C1=C23)* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108091006031 fluorescent proteins Proteins 0.000 description 1
- 102000034387 fluorescent proteins Human genes 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000001738 genotoxic Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000003824 heptacenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC=CC=C7C=C6C=C5C=C4C=C3C=C12)* 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 125000001633 hexacenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C12)* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 101700063973 lgg-1 Proteins 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 108010046177 locteron Proteins 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- MAJTXTYGACTQGY-UHFFFAOYSA-N methylcyclobutane Chemical class [CH2+][C]1CCC1 MAJTXTYGACTQGY-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229920001239 microRNA Polymers 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000016472 negative regulation of viral reproduction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 201000002674 obstructive nephropathy Diseases 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 230000036220 oral bioavailability Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 150000005324 oxide salts Chemical class 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 125000003933 pentacenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C12)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- UGTYTOKVOXBJBZ-LINPMSLLSA-N peramivir hydrate Chemical compound O.O.O.O.CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N UGTYTOKVOXBJBZ-LINPMSLLSA-N 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 125000001828 phenalenyl group Chemical group C1(C=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000001388 picenyl group Chemical group C1(=CC=CC2=CC=C3C4=CC=C5C=CC=CC5=C4C=CC3=C21)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920003250 poly(2-hydroxyethyl methacrylate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LCPMNMXCIHBTEX-UHFFFAOYSA-M potassium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [K+].CC(O)C(O)=O.CC(O)C([O-])=O LCPMNMXCIHBTEX-UHFFFAOYSA-M 0.000 description 1
- RYXIBQLRUHDYEE-UHFFFAOYSA-M potassium;5-(cyclohexen-1-yl)-3-[(4-methoxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylate Chemical compound [K+].C1CC(OC)CCC1N(C1=C(SC(=C1)C=1CCCCC=1)C([O-])=O)C(=O)C1CCC(C)CC1 RYXIBQLRUHDYEE-UHFFFAOYSA-M 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000000754 repressing Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 230000000284 resting Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000003530 single readout Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- LLVQEXSQFBTIRD-UHFFFAOYSA-M sodium;2,3,4-trihydroxy-4-oxobutanoate;hydrate Chemical compound O.[Na+].OC(=O)C(O)C(O)C([O-])=O LLVQEXSQFBTIRD-UHFFFAOYSA-M 0.000 description 1
- KMPHTYSTEHXSTL-UHFFFAOYSA-M sodium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O.CC(O)C([O-])=O KMPHTYSTEHXSTL-UHFFFAOYSA-M 0.000 description 1
- VDZDAHYKYRVHJR-UHFFFAOYSA-M sodium;2-hydroxypropanoate;hydrate Chemical compound [OH-].[Na+].CC(O)C(O)=O VDZDAHYKYRVHJR-UHFFFAOYSA-M 0.000 description 1
- SSERCMQZZYTNBY-UHFFFAOYSA-M sodium;3-[(4-hydroxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]-5-phenylthiophene-2-carboxylate Chemical compound [Na+].C1CC(C)CCC1C(=O)N(C1=C(SC(=C1)C=1C=CC=CC=1)C([O-])=O)C1CCC(O)CC1 SSERCMQZZYTNBY-UHFFFAOYSA-M 0.000 description 1
- OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 description 1
- DGPIGKCOQYBCJH-UHFFFAOYSA-M sodium;acetic acid;hydroxide Chemical compound O.[Na+].CC([O-])=O DGPIGKCOQYBCJH-UHFFFAOYSA-M 0.000 description 1
- VBGUQBPWJMPQBI-UHFFFAOYSA-M sodium;butanedioic acid;4-hydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)CCC(O)=O.OC(=O)CCC([O-])=O VBGUQBPWJMPQBI-UHFFFAOYSA-M 0.000 description 1
- JISIBLCXFLGVJX-UHFFFAOYSA-M sodium;butanedioic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)CCC(O)=O JISIBLCXFLGVJX-UHFFFAOYSA-M 0.000 description 1
- KIJIBEBWNNLSKE-UHFFFAOYSA-M sodium;oxalic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)C(O)=O KIJIBEBWNNLSKE-UHFFFAOYSA-M 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- 231100000721 toxic potential Toxicity 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000005423 trihalomethanesulfonamido group Chemical group 0.000 description 1
- 125000005152 trihalomethanesulfonyl group Chemical group 0.000 description 1
- 125000003960 triphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C3=CC=CC=C3C12)* 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
Description
The compounds and methods disclosed herein shift the focus of viral drug development away from the targeting of viral proteins to the development of drugs that target and enhance the host’s innate antiviral response. Such compounds and methods are likely to be more effective, less susceptible to the emergence of viral résistance, cause fewer side effects and be effective against a range of different viruses.
The RIG-I pathway is intimately involved in regulating the innate immune response to RNA virus infections. RIG-I agonists are expected to be useful for the treatment of many viruses including, without limitation, HCV, influenza, and West Nile virus. Accordingly, the présent disclosure relates to compounds and methods for treating viral infection, including infection by RNA viruses, wherein the compounds can modulate the RIG-I pathway.
One embodiment of the présent disclosure includes a compound represented by the formula
Formula 1 wherein a dashed line indicates the presence or absence of a bond; R1 may be Ra, OR2 or NR2R3; each Ra may independently be independently H, optionally substituted hydrocarbyl, optionally substituted aryl, optionally substituted heteroaryl; R2 and R3 may each independently be Ra, CORa, or SO2Ra; Y1, Y2, Y3 and Y4 may each independently be CR4 or N; each R4 may independently be R2, ORa, NR2R3. SRa, SORa, SO2Ra, SO2NHRa NCORa, halogen, trihalomethyl, CN, S=O, or nitro; R5 may be Ra, CORa, SO2Ra, or is not présent; V may be CR2, CR2R3, C=O, COCR2R3, or C=NR2; and, W and X may each independently be N, NRa, O, S, CR2R4or CR4.
Some embodiments of the présent disclosure include a compound represented by the formula (the “KIN1000” compound):
Additional embodiments include a compound represented by the formula
R16 wherein R10, R13, R14, R16, R17, R18, R19, R20, R21, and R22 are independently Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl; each Rb is independently H or C1.3 hydrocarbyl, and each Rc is independently H or Cv3 alkyl.
Further embodiments of the présent disclosure include a compound represented by the formula (the “KIN1148” compound):
H
Some embodiments of the présent disclosure include a pharmaceutical composition comprising any of the compounds as described herein.
Some embodiments of the présent disclosure include methods of treating or preventing a viral infection in a vertebrate comprising administering to the vertebrate a pharmaceutical composition as described herein. In some embodiments, the viral infection is caused by a virus from one or more of the following families: Arenaviridae, Astroviridae, Birnaviridae, Bromoviridae, Bunyaviridae, Caliciviridae, Closteroviridae, Comoviridae, Cystoviridae, Flaviviridae, Flexiviridae, Hepevirus, Leviviridae, Luteoviridae, Mononegavirales, Mosaic Viruses, Nidovirales, Nodaviridae, Orthomyxoviridae, Picobirnavirus, Picornaviridae, Potyviridae, Reoviridae, Retroviridae, Sequiviridae, Tenuivirus, Togaviridae, Tombusviridae, Totiviridae, Tymoviridae, Hepadnaviridae, Herpesviridae, Paramyxoviridae or Papillomaviridae. In some embodiments, the viral infection is influenza virus, Hepatitis C virus, West Nile virus, SARS-coronavirus, poliovirus, measles virus, Dengue virus, yellow fever virus, tick-borne encephalitis virus, Japanese encephalitis virus, St. Louis encephalitis virus, Murray Valley virus, Powassan virus, Rocio virus, louping-ill virus, Banzi virus, llheus virus, Kokobera virus, Kunjin virus, Alfuy virus, bovine diarrhea virus, Kyasanur forest disease virus, respiratory syncytial virus or HIV.
Some embodiments of the methods of the présent disclosure include administering any of the pharmaceutical compositions described herein as an adjuvant for a prophylactic or therapeutic 3 vaccine. In some embodiments, the method includes vaccinating a vertebrate by additionally administering a vaccine against influenza virus, Hepatitis C virus, West Nile virus, SARScoronavirus, poliovirus, measles virus, Dengue virus, yellow fever virus, tick-borne encephalitis virus, Japanese encephalitis virus, St. Louis encephalitis virus, Murray Valley virus, Powassan virus, Rocio virus, louping-ill virus, Banzi virus, llheus virus, Kokobera virus, Kunjin virus, Alfuy virus, bovine diarrhea virus, Kyasanur forest disease virus or HIV.
Some embodiments of the présent disclosure include methods of modulating the innate immune response in a eukaryotic cell, comprising administering to the cell any of the compounds as described herein. In some embodiments the cell is in vivo. In other embodiments the cell is in vitro.
Brief Description of the Drawings
Figure 1 shows validation and characterization of compound KIN1000 (“RLU” = relative luciferase units). In Figure 1A, initial “hit” compounds were validated by demonstrating dosedependent induction of the ΙΡΝβ-luciferase (ΙΡΝβ-LUC, left), ISG56-luciferase (ISG56-LUC, center), and the ISG54-luciferase (ISG54-LUC, right) reporter genes. Figure 1B confirms the specificity of Kl N1000, which does not induce the non-specific β-actin promoter (“0.5% DMSO” = vehicle control; “10μΜ KIN1000” = β-actin-luciferase reporter in presence of KIN1000; “10μΜ Compound X” = positive control β-actin induction). In Figure 1C, the MTS assay demonstrated that KIN1000 did not show évident cytotoxicity to human cells treated for 48 hours with the compound. The O.D. value that represents 50% cell mortality is shown by a horizontal line, also demonstrating that the CC50 of KIN1000 is greaterthan 20μΜ.
Figure 2 shows activation of transcription factors by KIN1000. In Figure 2A, HeLa cells treated with increasing amounts of KIN1000 showed dose-dependent increase in IRF-3 translocation to the nucléus, quantified by nuclear intensity minus cytoplasmic intensity (“normalized nuclear intensity”). In Figure 2B, HeLa cells treated with increasing amounts of KIN1000 showed dosedependent increase in NFkB translocation, quantified by nuclear intensity minus cytoplasmic intensity. “SeV” refers to Sendai virus infection, the positive control.
Figure 3 shows anti-viral activity of KIN1000. MRC5 cells treated with increasing amounts of KIN1000 showed dose-dependent decrease in infection by influenza virus.
Figure 4 shows Luminex® (Luminex Corp., Austin TX) quantified levels of cytokine expression induced by KIN1000. Human dendritic cells treated with increasing amounts of KIN1000 showed dose-dependent expression of cytokines including IL-8, MCP-1 (CCL2), and MIP-1a and β (CCL3 and CCL4, respectively).
Figure 5 shows induction of gene expression by KIN1000 and its dérivative compound KIN1148. Figure 5A shows gene expression levels of IFIT2 (left) and OAS1 (right) in HeLa cells over time from 4-24 hours post treatment with 10uM KIN1000 (grey) or KIN1148 (black). Figure 5B shows gene expression levels of IFIT2 in PH5CH8 cells (left) treated with Kl N1000 (solid grey bars) or KIN1148 (solid black bars), and in HeLa cells (right) treated with KIN1000 (grey striped bars) or 4
KIN1148 (black checked bars). In each test group, the three vertical bars represent 5, 10, and 20 μΜ compound (KIN1000 or KIN1148), respectively. Figure 5C shows gene expression levels of IFIT2 (left), OAS1 (center), and MxA (right) in primary HUVEC cells that were treated with 1μΜ Kl N1000 (grey) or 1μΜ KIN1148 (black).
Figure 6 shows antiviral activity of KIN1000 and KIN1148 against respiratory syncytial virus. Figure 6A shows that HeLa cells treated with increasing amount of KIN1000 and KIN1148 showed dose-dependent decrease in infection by RSV. Figure 6B shows that KIN1148 showed antiviral activity against RSV when drug is added up to 24 hours prior to infection.
Figure 7 shows antiviral activity of KIN1148 against Influenza A virus Udorn/72. H292 cells (left) and HEK293 cells (right) treated with 2μΜ (H292) or 10μΜ (HEK293) of KIN1148 showed decrease in infection by virus.
Figure 8 shows antiviral activity of KIN1148 against Dengue virus type 2. Huh 7 cells treated with increasing amounts of KIN1148 showed dose-dependent decrease in infection by virus.
Figure 9 shows antiviral activity of KIN1148 against Hepatitis B virus. HepAD38 cells treated with increasing amounts of KIN1148 showed dose-dependent decrease in supernatant levels of virus. The O.D. value that represents no HBV in the supernatant is shown by a horizontal line labeled “NO HBV CELLS.”
Figure 10 shows IgG antibody production induced by KIN1000 and KIN1148 in vivo. Animais (Lewis female rats, 10-12 weeks old) were vaccinated with suspensions of OVA in PBS, OVA+polyl:C, OVA+KIN1000 or OVA+KIN1148 subcutaneously in the footpad and base of tail (0.025 mL injection volume per site). Animais were boosted identically at 2 and 8 weeks post priming. Animais were bled at the indicated time points, sera was prepared and antibody levels were detected by ELISA. OD450 values for vaccine préparations containing KIN1000 (large checked bars) and KIN1148 (horizontal striped bars) were normalized to values obtained from animais that received OVA in PBS alone as vaccines. Poly l:C (small checked bars) was used as a control adjuvant.
Figure 11 shows cellular response elicited by KIN compound vaccination. Delatyed type hypersensitivity responses elicited 2 weeks after the first boost (4 weeks post prime) were measured. Animais were challenged by injection of 0.02 mL of PBS (left ear pinna) or 0.02 mL of OVA (1 mg/mL) in PBS (right ear pinna) at indicated time point. 24 hours later ear thickness was measured with calipers. The calculated différence between right ear and left ear is shown. “OVA+K1148” (vertical striped bar) = différence in ear thickness in animal injected with vaccine containing KIN1148. Poly l:C (“OVA+pl:C;” horizontal striped bar) was used as a control adjuvant.
Detailed Description
The présent disclosure provides compounds and methods that shift the focus of viral treatments away from the targeting of viral proteins to the development of drugs that target and enhance the host (patient’s) innate antiviral response. Such compounds and methods are likely to be 5 more effective, less susceptible to the emergence of viral résistance, cause fewer side effects and be effective against a range of different viruses.
The RIG-I pathway is intimately involved in regulating the innate immune response to RNA virus infections. RIG-I is a cytosolic pathogen récognition receptor that is essential for triggering immunity to a wide range of RNA viruses. RIG-I is a double-stranded RNA helicase that binds to motifs within the RNA virus genome characterized by homopolymeric stretches of uridine or polymeric U/A motifs. Binding to RNA induces a conformation change that relieves RIG-I signaling repression by an autologous repressor domain, thus allowing RIG-I to signal downstream through its tandem caspase activation and recruitment domains (CARDs). RIG-I signaling is dépendent upon its NTPase activity, but does not require the helicase domain. RIGI signaling is silent in resting cells, and the repressor domain serves as the on-off switch that governs signaling in response to virus infection.
RIG-I signaling is transduced through IPS-1 (also known as Cardif, MAVs, and VISA), an essential adaptor protein that résides in the outer mitochondrial membrane. IPS-1 recruits a macromolecular signaling complex that stimulâtes the downstream activation of IRF-3, a transcription factor that induces the expression of type I IFNs and virus-responsive genes that control infection. Compounds that trigger RIG-I signaling directly or through modulation of RIG-I pathway components, including IRF-3, présent attractive therapeutic applications as antivirals or immune modulators.
A high-throughput screening approach was used to identify compounds that modulate the RIG-I pathway, a key regulator of the cellular innate immune response to RNA virus infection. In particular embodiments, validated RIG-I agonist lead compounds were demonstrated to specifically activate interferon regulatory factor-3 (IRF-3). In additional embodiments they exhibit one or more of the following: they induce the expression of interferon-stimulated genes (ISGs), hâve low cytotoxicity in cell-based assays, are suitable for analog development and SAR studies, hâve drug-like physiochemical properties, and hâve antiviral activity against influenza A virus and/or HCV.
As discussed below, these compounds represent a new class of potential antiviral therapeutics. Although the disclosure is not bound by a spécifie mechanism of action of the compounds in vivo, the compounds are selected for their modulation of the RIG-I pathway. In certain embodiments, the modulation is activation of the RIG-I pathway. Compounds and methods disclosed herein function to, one or more of, decrease viral protein, viral RNA, and infectious virus in cell culture models of HCV and/or influenza virus.
In one embodiment, the disclosure herein relates to a class of compounds of represented by the following formula:
Formula 1
wherein a dashed line indicates the presence or absence of a bond; R1 may be Ra, OR2 or NR2R3; each Ra may independently be independently H, optionally substituted hydrocarbyl, optionally substituted aryl, optionally substituted heteroaryl; R2 and R3 may each independently be Ra, CORa, or SO2Ra; Y1, Y2, Y3 and Y4 may each independently be CR4 or N; each R4 may independently be R2, ORa, NR2R3 SRa, SORa, SO2Ra, SO2NHRa NCORa, halogen, trihalomethyl, CN, S=O, or nitro; R5 may be Ra, CORa, SO2Ra, or is not présent; V may be CR2, CR2R3, C=O, COCR2R3, or C=NR2; and, W and X may each independently be N, NRa, O, S, CR2R4or CR4.
With respect to Formula 1, Y1 may be CR4 or N. In some embodiments, Y1 is CR4.
With respect to Formula 1, Y2 may be CR4 or N. In some embodiments, Y2 is CR4.
In some embodiments, Y1 and Y2 are both CR4, and togetherform an additional heterocyclic ring optionally substituted by R18. In some embodiments, V may be:
With respect to Formula 1, Y3 may be CR4 or N. In some embodiments, Y3 is CR4.
With respect to Formula 1, Y4 may be CR4 or N. In some embodiments, Y4 is CR4.
In some embodiments, Y1, Y2, Y3 and Y4 are CR4. In some embodiments, Y1, Y2, Y3 and Y4 are
CH. In some embodiments, Y1 and Y2 are
Some embodiments include compounds represented by any of Formulas 2-12.
Formula 7
Formula 3
R16
Formula 9
Formula 6
With respect to any relevant structural feature herein, each Ra can independently be H; optionally substituted hydrocarbyl, such as C-|.12 or C^e hydrocarbyl; optionally substituted aryl, such as optionally substituted C6-i2 aryl, including optionally substituted phenyl; optionally substituted heteroaryl, including optionally substituted C2.-|2 heteroaryl, such as optionally substituted pyridinyl, optionally substituted furyl, optionally substituted thienyl, etc. In some embodiments, each Ra can independently be H, or C-m2 alkyl, including: linear or branched alkyl having the formula CaHa+1, or cycloalkyl having the formula CaH^, wherein a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, such as linear or branched alkyl of the formula: CH3, C2H5, C3H7, C4H9, CsHn, C6H13, C7H15, C8H17i C9H19, C1oH21, etc., or cycloalkyl of the formula: C3H5, C4H7, C5H9, CeHn, C7H13, C8H15i C9Hi7, Ci9Hi9, etc.
With respect to Ra, in some embodiments, the aryl group is substituted with halogen, trihalomethyl, alkoxy, alkylamino, OH, CN, alkylthio, arylthio, sulfoxide, arylsulfonyl, alkylsulfonyl, carboxylic acid, nitro or acylamino.
With respect to Ra, in some embodiments, the heteroaryl group is single or fused. In some embodiments, the single heteroaryl group is imidazole. In some embodiments, the fused heteroaryl group is benzimidazole. In some embodiments, the heteroaryl group is substituted with halogen, trihalomethyl, alkoxy, alkylamino, OH, CN, alkylthio, arylthio, sulfoxide, arylsulfonyl, alkylsulfonyl, carboxylic acid, nitro or acylamino. In some embodiments, the alkyl group is branched, cyclic or polycyclic.
With respect to Ra, a hydrocarbyl may be alkyl, alkenyl, or alkynyl. In some embodiments, the alkyl group is substituted with halogen, trihalomethyl, alkoxy, alkylamino, OH, CN, heteroaryl, alkylthio, arylthio, sulfoxide, arylsulfonyl, alkylsulfonyl, carboxylic acid, nitro, or acylamino. In some embodiments, the heteroaryl group is single or fused. In some embodiments, the single heteroaryl group is imidazole. In some embodiments, the fused heteroaryl group is benzimidazole. In some embodiments, the alkenyl group is branched, cyclic or polycyclic. In some embodiments, the alkenyl group is substituted with halogen, trihalomethyl, alkoxy, alkylamino, OH, CN, heteroaryl, alkylthio, arylthio, sulfoxide, arylsulfonyl, alkylsulfonyl, carboxylic acid, nitro, or acylamino.
With respect to any relevant structural feature herein, Rb may be H, or C-1.3 hydrocarbyl, such as CH3, C2H5, C3H7, cyclopropyl, CH=CH2, CH2CH=CH2, C^CH, CH2C^CH, etc.
With respect to any relevant structural feature herein, Rc may be H, or C-|.3 alkyl, such as CH3, C2H5, C3H7, cyclopropyl, etc. In some embodiments, Rc is H.
With respect to any relevant formula or structural depiction herein, such as Formula 1, Formula 2, Formula 3, or Formula 4, R1 is Ra, OR2 or NR2R3. In some embodiments, R1 is optionally substituted phenyl. In some embodiments, R1 is unsubstituted phenyl. In some embodiments, R1 is optionally substituted naphthyl. In some embodiments, R1 is unsubstituted naphthyl.
In some embodiments, R1 is
In some embodiments, R1 is
With respect to any relevant structural feature herein, R2 may be Ra, CORa, or SO2Ra. In some embodiments, R2 may be H, methyl, ethyl, a propyl (e.g. n-propyl, isopropyl, etc.), cyclopropyl, a butyl, cyclobutyl or an isomer thereof, a pentyl, cyclopentyl or an isomer thereof, a hexyl, a cyclohexyl or an isomer thereof, etc. In some embodiments, R2is H.
With respect to any relevant structural feature herein, R3 may be Ra, CORa, or SO2Ra. In some embodiments, R3 may be H, methyl, ethyl, a propyl (e.g. n-propyl, isopropyl, etc.), cyclopropyl, a butyl, cyclobutyl or an isomer thereof, a pentyl, cyclopentyl or an isomer thereof, a hexyl, a cyclohexyl or an isomer thereof, etc. In some embodiments, R3 is H.
With respect to any relevant structural feature herein, each R4 may independently be R2, ORa, CORa, CO2Ra, OCORa, CONR2R3 NR2R3 NRbCORa, SRa, SORa, SO2Ra, SO2NRaRb, NCORa, halogen, trihalomethyl, CN, S=O, nitro, or C2.5 heteroaryl. In some embodiments, R4 is H.
Generally R5 and Rs-R32, may be H or any substituent, such as a substituent having from 0 to 6 carbon atoms and from 0 to 5 heteroatoms independently selected from: O, N, S, F, Cl, Br, and I, and/or having a molecular weight of 15 g/mol to 300 g/mol. Any of R5 and R8-R32 may comprise: a) 1 or more alkyl moieties optionally substituted with, or optionally connected by, b) 1 or more functional groups, such as C=C, C=C, CO, CO2, CON, NCO2, OH, SH, O, S, N, N=C, F, Cl, Br, I, CN, NO2, CO2H, NH2, etc.; or may be a substituent having no alkyl portion, such as F, Cl, Br, I, NO2, CN, NH2, OH, COH, CO2H, etc.
With respect to any relevant structural feature herein, In some embodiments, R5 may be Ra, CORa, SO2Ra, or may not be présent. Some non-limiting examples of R5 may include H or C-|_3 alkyl, such as CH3, C2H5, C7, cyclopropyl, etc. In some embodiments, R5 may be CH3 In some embodiments, R5 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R8 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R8 is H, CH3. CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2C^CH, or NO2. In some embodiments, R8 is H.
morpholino
With respect to any relevant formula or structural depiction above, some non-limiting examples of R9 may include Rb, CORb, CO2Rb, CONRbR°, NRbCORc, SO2NRbRc, CF3, CN, or C2.5 heterocyclyl. In some embodiments, R9 is H, CH3 CH2CH3, SO2NH2, or CH2C^CH. In some embodiments, R9 is H, CH3, CH2CH3, CH2CH2CH3, CH2CH=CH2, or ΟΗ2ΟξΟΗ. In some embodiments, R9 is CH2C^CH. In some embodiments, R9 is H.
SO2NRbRc
NRbCORc
With respect to any relevant formula or structural depiction above, some non-limiting examples of R10 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R10 is H, CH3. CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2CeCH, or NO2. In some embodiments, R10 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R11 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R11 is H, CH3] CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2CeCH, or NO2. In some embodiments, R11 is H, Cl or Br. In some embodiments, R11 is Cl. In some embodiments, R11 is Br. In some embodiments, R11 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R12 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R12 is H, CH3. CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2CeCH, or NO2. In some embodiments, R12 is H, Cl, or SO2NH2. In some embodiments, R12 is H. In some embodiments, R12 is Cl. In some embodiments, R12 is SO2NH2. In some embodiments, R12 is H.
v°>
In some embodiments, R11 and R12 are together: / θ
With respect to any relevant formula or structural depiction above, some non-limiting examples of R13 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R13 is H, CH3] CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2C^CH, or NO2. In some embodiments, R13 is H or Cl. In some embodiments, R13 is H. In some embodiments, R13 is Cl.In some embodiments, R11 and R13 are Cl.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R14 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, CF3, CN, NO2, F, Cl, Br, or I. In some embodiments, R14 is H, CH3. CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, CH2C=CH, or NO2. In some embodiments, R14 is H.
In some embodiments, R10 and R14 are H. In some embodiments, R10, R12, and R14 are H. In some embodiments, R10, R13, and R14 are H. In some embodiments, R10, R11, R13, and R14 are H. In some embodiments, R10, R11, R12, and R14 are H. In some embodiments, R10, R11, R12, R13, and R14 are H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R16 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br,or C2.5 heterocyclyl. In some embodiments, R16 is H, CH3 CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2C=CH, or NO2. In some embodiments, R16 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R17 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2_5 heterocyclyl. In some embodiments, R17 is H, CH3. CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2CeCH, or NO2. In some embodiments, R17 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R18 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R18 is H, CH3, CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2CeCH, or NO2. In some embodiments, R18 is H or CH3. In some embodiments, R18 is H. In some embodiments, R18 is CH3. In some embodiments, R18 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R19 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, or C2.5 heterocyclyl. In some embodiments, R19 is H, CH3 CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2CeCH, or NO2. In some embodiments, R19 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R20 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R20 is H, CH3 CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, CH2CeCH, or NO2. In some embodiments, R20 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R21 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R21 is H, CH3,
Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2i SO2NH2, morpholino, CH2CeCH, or NO2. In some embodiments, R21 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R22 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R22 is H, CH3. CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, or NO2. In some embodiments, R22 is H.
In some embodiments, R19, R20, R21, and R22 are H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R23 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R23 is H, CH3> CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, CH2CeCH, or NO2. In some embodiments, R23 is H or SO2NH2. In some embodiments, R23 is H. In some embodiments, R23 is SO2NH2.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R24 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R24 is H, CH3 CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, or NO2. In some embodiments, be R24 may H.
In some embodiments, R23 and R24 are H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R25 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, or C2.5 heterocyclyl. In some embodiments, R25 is H, CH3iCH2CH3, N(CH3)2, SO2NH2, morpholino, CH2C^CH, or NO2. In some embodiments, R25 is CH3 or H. In some embodiments, R25 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R26 may include Rb, CF3, CN, or NO2. In some embodiments, R26 is H, CH3. or CH2CH3. In some embodiments, R26 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R27 may include Rb, ORb, SRb, CORb, CO2Rb, CONRbRc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R27 is H, CH3, CH2CH3, Cl, Br, OH, OCH3, SCH3, SO2NH2, ΟΗ2ΟξΟΗ, or NO2. In some embodiments, R27 is H, (CH2)3CH3, CH2CH2OCH3, CH2CH2N(CH3)2, CH2CH2-morpholino, or CH2CH2SCH3. In some embodiments, R27 is H. In some embodiments, R27 is (CH2)3CH3. In some embodiments, R27 is CH2CH2OCH3. In some embodiments, R27 is CH2CH2N(CH3)2. In some embodiments, R27 is CH2CH2-morpholino. In some embodiments, R27 is CH2CH2SCH3.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R28 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc,
SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R28 is H, CH3i CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2CeCH, or NO2. In some embodiments, R28 is H, CH2CH3, OCH3, N(CH3)2, morpholino, or SCH3. In some embodiments, R28 is H. In some embodiments, R28 is CH2CH3. In some embodiments, R28 is OCH3. In some embodiments, R28 is CN(CH3)2. In some embodiments, R28 is morpholino. In some embodiments, R28 is SCH3.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R29 may include Rb, ORb, SRb, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R29 is H, CH3i or CH2CH3. In some embodiments, R29 is H.
In some embodiments, R8 and R29 are H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R30 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, or I. In some embodiments, R30 is H, CH3. CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, CH2CeCH, or NO2. In some embodiments, R30 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R31 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R31 is H, CH3] CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2CeCH, or NO2. In some embodiments, R31 is H.
With respect to any relevant formula or structural depiction above, some non-limiting examples of R32 may include Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl. In some embodiments, R32 is H, CH3. CH2CH3, Cl, Br, OH, OCH3, SCH3, NH2, NHCH3, N(CH3)2, SO2NH2, morpholino, CH2CeCH, or NO2. In some embodiments, R32 is H or NO2. In some embodiments, R32 is H. In some embodiments, R32 is NO2.
In some embodiments, R30, R31, and R32 are H. In some embodiments, R31 and R32 are H.
NHCH3, N(CH3)2, SO2NH2, morpholino, CH2CsCH, or NO2. In some embodiments, R33 is H.
In another embodiment disclosed herein the compound is (the “KIN1000” compound)
Unless otherwise indicated, any reference to a compound herein by structure, formula, name or any other means, includes pharmaceutically acceptable salts, such as sodium, potassium, and ammonium salts; prodrugs, such as ester prodrugs; alternate solid forms, such as polymorphs, solvatés, hydrates, etc.; tautomers; or, any other Chemical species that may rapidly convert to a compound described herein under conditions in which the compounds are used as described herein.
Unless stereochemistry is unambiguously depicted, any structure, formula or name for a compound can refer to any stereoisomer or any mixture of stereoisomers of the compound.
As used herein, the term “functional group” refers to an atom or a group of atoms that hâve similar Chemical properties whenever they occur in different compounds, and as such the functional group defines the characteristic physical and Chemical properties of families of organic compounds.
Unless otherwise indicated, when any compound or Chemical structural feature (collectively referred to herein as a “compound”), such as for example alkyl, aryl, etc., is referred to as being “optionally substituted,” that compound can hâve no substituents (in which case it is “unsubstituted”), or it can include one or more substituents (in which case it is “substituted”). The term “substituent” has the ordinary meaning known to one of ordinary skill in the art. In some embodiments, the substituent may be an ordinary organic moiety known in the art, which can hâve a molecular weight (e.g., the sum of the atomic masses of the atoms of the substituent) of 15 g/mol to 50 g/mol, 15 g/mol to 100 g/mol, 15 g/mol to 150 g/mol,15 g/mol to 200 g/mol, 15 g/mol to 300 g/mol, or 15 g/mol to 500 g/mol. In some embodiments, the substituent comprises: 0-30, 0-20, 0-10, or 0-5 carbon (C) atoms; and/or 0-30, 0-20, 0-10, or 0-5 heteroatoms including N, O, S, Si, F, Cl, Br, or I; provided that the substituent comprises at least one atom including C, N, O, S, Si, F, Cl, Br, or I in a substituted compound. Examples of substituents include, but are not limited to, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, acyl, acyloxy, alkylcarboxylate, thiol, alkylthio, cyano, halo, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxyl, trihalomethanesulfonyl, trihalomethanesulfonamido, amino, etc. For convenience, the term “molecular weight” is used with respect to a moiety or part of a molécule to indicate the sum of the atomic masses of the atoms in the moiety or part of a molécule, even though it may not be a complété molécule.
As used herein, the term “hydrocarbyl” has the broadest meaning generally understood in the art, and can include a moiety composed of carbon and hydrogen. Some examples can include alkyl, alkenyl, alkynyl, aryl, etc., and combinations thereof, and can be linear, branched, cyclic, or a combination thereof. Hydrocarbyl can be bonded to any other number of moieties (for example, can be bonded to one other group, such as -CH3, -CH=CH2, etc.; two other groups, such as -phenyl-, -C^C-, etc.; or any number of other groups) that the structure can bear, and in some embodiments, can contain from one to thirty-five carbon atoms. Examples of hydrocarbyl groups include but are not limited to C-ι alkyl, C2 alkyl, C2 alkenyl, C2 alkynyl, C3 alkyl, C3 alkenyl, C3 alkynyl, C4 alkyl, C4 alkenyl, C4 alkynyl, C5 alkyl, C5 alkenyl, C5 alkynyl, C6 alkyl, C6 alkenyl, C6 alkynyl, phenyl, etc.
As used herein the term “alkyl” has the broadest meaning generally understood in the art, and can include a moiety composed of carbon and hydrogen containing no double or triple bonds and not having any cyclic structure. Alkyl can be linear alkyl, branched alkyl, cycloalkyl, or a combination thereof, and in some embodiments, can contain from one to thirty-five carbon atoms. In some embodiments, alkyl can include Ci.10 linear alkyl, such as methyl (-CH3), ethyl (CH2CH3), n-propyl (-CH2CH2CH3), n-butyl (-CH2CH2CH2CH3), n-pentyl (-CH2CH2CH2CH2CH3), n-hexyl (-CH2CH2CH2CH2CH2CH3), etc.; C3.w branched alkyl, such as C3H7 (e.g. iso-propyl), C4H9 (e.g., branched butyl isomers), C5Hn (e.g., branched pentyl isomers), C6H13 (e.g., branched hexyl isomers), C7H15 (e.g., branched heptyl isomers), etc.; C3.10 cycloalkyl, such as C3H5 (e.g. cyclopropyl), C4H7 (e.g., cyclobutyl isomers such as cyclobutyl, methylcyclopropyl, etc.), C5H9 (e.g., cyclopentyl isomers such as cyclopentyl, methylcyclobutyl, dimethylcyclopropyl, etc.) CeHn (e.g., cyclohexyl isomers), C7H13 (e.g., cycloheptyl isomers), etc.; and the like.
The terms “alkyl,” “alkenyl” and “alkynyl” refer to substituted and unsubstituted alkyls, alkenyls and alkynyls, respectively. An alkyl group can be optionally substituted as defined herein.
Substituted alkyls, alkenyls and alkynyls refers to alkyls, alkenyls and alkynyls substituted with one to five substituents including H, lower alkyl, aryl, alkenyl, alkynyl, arylalkyl, alkoxy, aryloxy, arylalkoxy, alkoxyalkylaryl, alkylamino, arylamino, NH2, OH, CN, NO2, OCF3, CF3, F, 1-amidine, 2-amidine, alkylcarbonyl, morpholinyl, piperidinyl, dioxanyl, pyranyl, heteroaryl, furanyl, thiophenyl, tetrazolo, thiazolyl, isothiazolyl, imidazolyl, thiadiazolyl, thiadiazole S-oxide, thiadiazole S,S-dioxide, pyrazolo, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, SR, SOR, SO2R, CO2R, COR, CONR’R”, CSNR’R” and SOnNR’R”.
As used herein, either alone or in combination, the term alkynyl refers to a functional group comprising a straight-chain or branched-chain hydrocarbon containing from 2 to 20 carbon atoms and having one or more carbon-carbon triple bonds and not having any cyclic structure. An alkynyl group may be optionally substituted as defined herein. Examples of alkynyl groups include, without limitation, ethynyl, propynyl, hydroxypropynyl, butynyl, butyn-1-yl, butyn-2-yl, 3methylbutyn-1-yl, pentynyl, pentyn-1-yl, hexynyl, hexyn-2-yl, heptynyl, octynyl, nonynyl, decynyl, undecynyl, dodecynyl, tridecynyl, tetradecynyl, pentadecynyl, hexadecynyl, heptadecynyl, octadecynyl, nonadecynyl, eicosynyl, and the like.
The term alkylene as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (-CH2-). Unless otherwise specified, the term alkyl may include alkylene groups.
As used herein, either alone or in combination, the term alkylcarbonyl or alkanoyl refers to a functional group comprising an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of alkylcarbonyl groups include, without limitation, methylcarbonyl, ethylcarbonyl, and the like.
As used herein, either alone or in combination, the term heteroalkyl refers to a functional group comprising a straight-chain or branched-chain hydrocarbon containing from 1 to 20 atoms linked exclusively by single bonds, where at least one atom in the chain is a carbon and at least one atom in the chain is O, S, N, or any combination thereof. The heteroalkyl group can be fully saturated or contain from 1 to 3 degrees of unsaturation. The non-carbon atoms can be at any interior position of the heteroalkyl group, and up to two non-carbon atoms may be consecutive, such as, e.g., -CH2-NH-OCH3. In addition, the non-carbon atoms may optionally be oxidized and the nitrogen may optionally be quaternized.
As used herein, either alone or in combination, the term “alkyloxy” or alkoxy refers to a functional group comprising an alkyl ether group. Examples of alkoxys include, without limitation, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tertbutoxy, and the like.
As used herein, either alone or in combination, the term hydroxy refers to the functional group hydroxyl (-OH).
As used herein, either alone or in combination, the term carboxyl or carboxy refers to the functional group -C(=O)OH or the corresponding carboxylate anion -C(=O)O-, Examples include, without limitation, formic acid, acetic acid, oxalic acid, benzoic acid. An O-carboxyl group refers to a carboxyl group having the general formula RCOO, wherein R is an organic moiety or group. A C-carboxyl group refers to a carboxyl group having the general formula COOR, wherein R is an organic moiety or group.
As used herein, either alone or in combination, the term oxo refers to the functional group =0. As used herein, the term “carbocyclic” has the broadest meaning generally understood in the art, and includes a ring or ring System wherein the ring atoms are ail carbon. Examples include, but are not limited to, phenyl, naphthyl, anthracenyl, cycloalkyl, cycloalkenyl, cycloalkynyl, etc., and combinations thereof.
As used herein, the term “heterocyclic” has the broadest meaning generally understood in the art, and includes a ring or ring System wherein at least one of the ring atoms is not carbon, such as N, O, S, etc. Examples include, but are not limited to, heteroaryl, cycloheteroalkyl, cycloheteroalkenyl, cycloheteroalkynyl, etc., and combinations thereof.
As used herein, either alone or in combination, the term “cycloalkyl,” “carbocyclicalkyl” and “carbocyclealkyl” refers to a functional group comprising a substituted or unsubstituted nonaromatic hydrocarbon with a non-conjugated cyclic molecular ring structure of 3 to 12 carbon atoms linked exclusively with carbon-carbon single bonds in the carbon ring structure. A cycloalkyl group can be monocyclic, bicyclic or polycyclic, and may optionally include one to three additional ring structures, such as, e.g., an aryl, a heteroaryl, a cycloalkenyl, a heterocycloalkyl, or a heterocycloalkenyl.
As used herein, either alone or in combination, the term lower cycloalkyl refers to a functional group comprising a monocyclic substituted or unsubstituted non-aromatic hydrocarbon with a non-conjugated cyclic molecular ring structure of 3 to 6 carbon atoms linked exclusively with carbon-carbon single bonds in the carbon ring structure. Examples of lower cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
As used herein the term “aryl” has the broadest meaning generally understood in the art, and can include an aromatic ring or aromatic ring System. An aryl group can be monocyclic, bicyclic or polycyclic, and may optionally include one to three additional ring structures; such as, for example, a cycloalkyl, a cycloalkenyl, a heterocycloalkyl, a heterocycloalkenyl, or a heteroaryl. The term aryl includes, without limitation, phenyl (benzenyl), thiophenyl, indolyl, naphthyl, tolyl, xylyl, anthracenyl, phenanthryl, azulenyl, biphenyl, naphthalenyl, 1-methylnaphthalenyl, acenaphthenyl, acenaphthylenyl, anthracenyl, fluorenyl, phenalenyl, phenanthrenyl, benzo[a]anthracenyl, benzo[c]phenanthrenyl, chrysenyl, fluoranthenyl, pyrenyl, tetracenyl (naphthacenyl), triphenylenyl, anthanthrenyl, benzopyrenyl, benzo[a]pyrenyl, benzo[e]fluoranthenyl, benzo[ghi]perylenyl, benzo[j]fluoranthenyl, benzo[k]fluoranthenyl, corannulenyl, coronenyl, dicoronylenyl, helicenyl, heptacenyl, hexacenyl, ovalenyl, pentacenyl, picenyl, perylenyl, tetraphenylenyl, etc.
Additionally, as used herein, either alone or in combination, the term “aryl,” hydrocarbyl aryl or “aryl hydrocarbon” can refer to a functional group comprising a substituted or unsubstituted aromatic hydrocarbon with a conjugated cyclic molecular ring structure of 3 to 12 carbon atoms. Substituted aryl refers to aryls substituted with one to five substituents including H, lower alkyl, aryl, alkenyl, alkynyl, arylalkyl, alkoxy, aryloxy, arylalkoxy, alkoxyalkylaryl, alkylamino, arylamino, NH2, OH, CN, NO2, OCF3, CF3, Br, Cl, F, 1-amidino, 2-amidino, alkylcarbonyl, morpholino, piperidinyl, dioxanyl, pyranyl, heteroaryl, furanyl, thiophenyl, tetrazolo, thiazole, isothiazolo, imidazolo, thiadiazole, thiadiazole S-oxide, thiadiazole S,S-dioxide, pyrazolo, oxazole, isoxazole, pyridinyl, pyrimidinyl, quinoline, isoquinoline, SR, SOR, SO2R, CO2R, COR, CONR’R”, CSNR’R”, SOnNR’R”, etc.
As used herein, either alone or in combination, the term “lower aryl” refers to a functional group comprising a substituted or unsubstituted aromatic hydrocarbon with a conjugated cyclic molecular ring structure of 3 to 6 carbon atoms. Examples of lower aryl groups include, without limitation, phenyl and naphthyl.
As used herein, either alone or in combination, the term heteroaryl refers to a functional group comprising a substituted or unsubstituted aromatic hydrocarbon with a conjugated cyclic molecular ring structure of 3 to 12 atoms, where at least one atom in the ring structure is a carbon and at least one atom in the ring structure is O, S, N, or any combination thereof. A heteroaryl group can be monocyclic, bicyclic or polycyclic, and may optionally include one to three additional ring structures, such as, e.g., an aryl, a cycloalkyl, a cycloalkenyl, a heterocycloalkyl, or a heterocycloalkenyl. Examples of heteroaryl groups include, without limitation, acridinyl, benzidolyl, benzimidazolyl, benzisoxazolyl, benzodioxinyl, dihydrobenzodioxinyl, benzodioxolyl, 1,3-benzodioxolyl, benzofuryl, benzoisoxazolyl, benzopyranyl, benzothiophenyl, benzo[c]thiophenyl, benzotriazolyl, benzoxadiazolyl, benzoxazolyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, carbazolyl, chromonyl, cinnolinyl, dihydrocinnolinyl, coumarinyl, dibenzofuranyl, furopyridinyl, furyl, indolizinyl, indolyl, dihydroindolyl, imidazolyl, indazolyl, isobenzofuryl, isoindolyl, isoindolinyl, dihydroisoindolyl, isoquinolyl, dihydroisoquinolinyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, phenanthrolinyl, phenanthridinyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolinyl, pyrrolyl, pyrrolopyridinyl, quinolyl, quinoxalinyl, quinazolinyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thiophenyl, thiazolyl, thiadiazolyl, thienopyridinyl, thienyl, thiophenyl, triazolyl, xanthenyl, and the like.
As used herein, either alone or in combination, the term lower heteroaryl refers to a functional group comprising a monocyclic or bicyclic, substituted or unsubstituted aromatic hydrocarbon with a conjugated cyclic molecular ring structure of 3 to 6 atoms, where at least one atom in the ring structure is a carbon and at least one atom in the ring structure is O, S, N, or any combination thereof.
The phenyl structure associated with some of the embodiments described herein is depicted below, This structure can be unsubstituted, as shown below, or can be substituted such that a substituent can independently be in any position normally occupied by a hydrogen atom when the structure is unsubstituted. Unless a point of attachment is indicated by -|, attachment may occur at any position normally occupied by a hydrogen atom.
Phenyl
Each Ra can independently be H; optionally substituted hydrocarbyl; optionally substituted aryl, such as optionally substituted phenyl or optionally substituted aryl; optionally substituted heteroaryl, such as optionally substituted pyridinyl, optionally substituted furyl, optionally substituted thienyl, etc. In some embodiments, each Ra can independently be H, or Ci.12 alkyl, including: linear or branched alkyl having the formula CaHa+1, or cycloalkyl having the formula CaHa.!, wherein a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, such as linear or branched alkyl of the formula: CH3, C2H5, C3H7, C4H9, CsHn, C6H13, C7H15, C8H17, C9H19, Ci0H21, etc., or cycloalkyl of the formula: C3H5, C4H7, C5H9, CeHn, C7H13, C8H15, C9H17, C10H19, etc.
The term “treat” includes one or more of the diagnosis, cure, mitigation, vaccination, augmentation of a therapy or prévention of disease in man or other animais
As used herein, the term “vertebrate” includes ail living vertebrates such as, without limitation, mammals, humans, birds, dogs, cats, livestock, farm animais, free-range herds, etc.
Many RNA viruses share biochemical, regulatory, and signaling pathways. These viruses include but are not limited to influenza virus (including avian and swine isolâtes), respiratory syncytial virus, Hepatitis C virus, West Nile virus, SARS-coronavirus, poliovirus, measles virus, Dengue virus, yellow fever virus, tick-borne encephalitis virus, Japanese encephalitis virus, St. Louis encephalitis virus, Murray Valley virus, Powassan virus, Rocio virus, louping-ill virus, Banzi virus, llheus virus, Kokobera virus, Kunjin virus, Alfuy virus, bovine diarrhea virus, and the Kyasanur forest disease virus. The compounds and methods disclosed herein can be used to treat these viruses.
Relevant taxonomie families of RNA viruses include, without limitation, Arenaviridae, Astroviridae, Birnaviridae, Bromoviridae, Bunyaviridae, Caliciviridae, Closteroviridae, Comoviridae, Cystoviridae, Flaviviridae, Flexiviridae, Hepevirus, Leviviridae, Luteoviridae, Mononegavirales, Mosaic Viruses, Nidovirales, Nodaviridae, Orthomyxoviridae, Paramyxoviridae, Picobirnavirus, Picornaviridae, Potyviridae, Reoviridae, Retroviridae, Sequiviridae, Tenuivirus, Togaviridae, Tombusviridae, Totiviridae, and Tymoviridae. The compounds and methods disclosed herein can be used to treat viruses within these families of viruses as part of a pharmaceutically acceptable drug formulation. Other relevant virus families include, without limitation, Hepadnaviridae, Herpesviridae, and Papillomaviridae.
Particular embodiments provide for pharmaceutical compositions comprising the compounds, alone or in combination with an antigen, for the purpose of treating and/or preventing disease in an animal including a vertebrate animal. As such, in some embodiments the pharmaceutical compositions can be used as vaccines.
The disclosure provides for the use of the compounds as adjuvants.
The compounds and methods disclosed herein can be additive or synergistic with other thérapies currently in development or use. For example, ribavirin and interferon-α provide an effective treatment for HCV infection when used in combination. Their efficacy in combination can exceed the efficacy of either drug product when used alone. The compositions of the disclosure can be administered alone or in combination or conjunction with interferon, ribavirin and/or a variety of small molécules that are being developed against both viral targets (viral proteases, viral polymerase, assembly of viral réplication complexes) and host targets (host proteases required for viral Processing, host kinases required for phosphorylation of viral targets such as NS5A, and inhibitors of host factors required to efficiently utilize the viral internai ribosome entry site, or IRES).
The compounds and methods disclosed herein could be used in combination or conjunction with, without limitation, adamantane inhibitors, neuraminidase inhibitors, alpha interferons, nonnucleoside or nucleoside polymerase inhibitors, NS5A inhibitors, antihistamines, protease inhibitors, helicase inhibitors, P7 inhibitors, entry inhibitors, IRES inhibitors, immune stimulators, HCV réplication inhibitors, cyclophilin A inhibitors, A3 adenosine agonists, and microRNA suppressors.
Cytokines that could be administered in combination or conjunction with the compounds and methods disclosed herein include, without limitation, IL-2, IL-12, IL-23, IL-27, or IFN-γ. New HCV drugs that are or will be available for potential administration in combination or conjunction with the compounds and methods disclosed herein include, without limitation, ACH-1625 (Achillion); Glycosylated interferon (Alios Biopharma); ANA598, ANA773 (Anadys Pharm); ATI0810 (Arisyn Therapeutics); AVL-181 (Avila Therapeutics); LOCTERON® (Biolex); CTS-1027 (Conatus); SD-101 (Dynavax Technologies); Clemizole (Eiger Biopharmaceuticals); GS-9190 (Gilead Sciences); GI-5005 (Globallmmune BioPharma); Resiquimod / R-848 (Graceway Pharmaceuticals); Albinterferon alpha-2b (Human Genome Sciences); IDX-184, IDX-320, IDX375 (Idenix); IMO-2125 (Idera Pharmaceuticals); INX-189 (Inhibitex); ITCA-638 (Intarcia Therapeutics); ITMN-191/RG7227 (Intermune); ITX-5061, ITX-4520 (iTherx Pharmaceuticals); MB11362 (Metabasis Therapeutics); Bavituximab (Peregrine Pharmaceuticals); PSI-7977, RG7128, PSI-938 (Pharmasset); PHX1766 (Phenomix); Nitazoxanide / ALINIA® (Romark Laboratories); SP-30 (Samaritan Pharmaceuticals); SCV-07 (SciClone); SCY-635 (Scynexis); TT-033 (Tacere Therapeutics); Viramidine/taribavirin (Valeant Pharmaceuticals); Telaprevir, VCH-759, VCH-916, VCH-222, VX-500, VX-813 (Vertex Pharmaceuticals); and PEG-INF Lambda (Zymogenetics).
New influenza and West Nile virus drugs that are or will be available for potential administration in combination or conjunction with the compounds and methods disclosed herein include, without limitation, neuraminidase inhibitors (Peramivir, Laninamivir); triple therapy neuraminidase inhibitors ribavirin, amantadine (ADS-8902); polymerase inhibitors (Favipiravir); reverse transcriptase inhibitor (ANX-201); inhaled chitosan (ANX-211); entry / binding inhibitors (Binding Site Mimetic, FLUCIDE™ (NanoViricides, West Haven, Connecticut); entry inhibitor (FLUDASE® (NexBio, San Diego, California); fusion inhibitor, (MGAWN1 for West Nile); host cell inhibitors (lantibiotics); cleavage of RNA genome (RNAi, RNAse L); immune stimulators (Interferon, Alferon-LDO; Neurokininl agonist, Homspera, Interferon Alferon N for West Nile); and TG21.
Other drugs for treatment of influenza and/or hepatitis that are available for potential administration in combination or conjunction with the compounds and methods disclosed herein include, without limitation:
Table 1. Hepatitis and influenza drugs
Branded Name | Generic Name | Approved Indications |
PEGASYS® (Genentech, South San Francisco, California) | PEGinterferon alfa-2a | Hepatitis C, Hepatitis B |
PEGINTRON® (Merck, | PEGinterferon alfa-2b | Hepatitis C |
Whitehouse Station, New Jersey) | ||
COPEGUS® (Roche Pharmaceuticals, Nutley, New Jersey) | Ribavirin | Hepatitis C |
REBETOL® (Schering Plough, Kenilworth, New Jersey) | Ribavirin | Hepatitis C |
— | Ribavirin | Hepatitis C |
TAMIFLU® (Roche Pharmaceuticals, Nutley, New Jersey) | Oseltamivir | Influenza A, B, C |
RELENZA® (GlaxoSmithKIine, London, UK) | Zanamivir | Influenza A, B, C |
— | Amantadine | Influenza A |
— | Rimantadine | Influenza A |
These agents can be incorporated as part of the same pharmaceutical composition or can be administered separately from the compounds of the disclosure, either concurrently or in accordance with another treatment schedule.
The compounds and methods disclosed herein can be additive or synergistic with other compounds and methods to enable vaccine development. By virtue of their antiviral and immune enhancing properties, the compounds can be used to affect a prophylactic or therapeutic vaccination. The compounds need not be administered simultaneously or in combination with other vaccine components to be effective. The vaccine applications of the compounds are not limited to the prévention or treatment of virus infection but can encompass ail therapeutic and prophylactic vaccine applications due to the general nature of the immune response elicited by the compounds.
As is understood by one of ordinary skill in the art, vaccines can be against viruses, bacterial infections, cancers, etc. and can include one or more of, without limitation, a live attenuated vaccine (LAIV), an inactivated vaccine (IIV; killed virus vaccine), a subunit (split vaccine); a subvirion vaccine; a purified protein vaccine; or a DNA vaccine. Appropriate adjuvants include one or more of, without limitation, water/oil émulsions, non-ionic copolymer adjuvants, e.g., CRL 1005 (Optivax™; Vaxcel Inc., Norcross, Ga.), aluminum phosphate, aluminum hydroxide, aqueous suspensions of aluminum and magnésium hydroxides, bacterial endotoxins, polynucleotides, polyelectrolytes, lipophilie adjuvants and synthetic muramyl dipeptide (norMDP) analogs such as N-acetyl-nor-muranyl-L-alanyl-D-isoglutamine, N-acetyl-muranyl-(6-Ostearoyl)-L-alanyl-D-isoglutamine or N-Glycol-muranyl-LalphaAbu-D-isoglutamine (Ciba-Geigy
Ltd.).
The pharmaceutical composition comprising a compound of the disclosure can be formulated in a variety of forms; e.g., as a liquid, gel, lyophilized, or as a compressed solid. The preferred form will dépend upon the particular indication being treated and discernible by one of ordinary skill in the art. In one embodiment, the disclosed RIG-I agonists include formulations for oral delivery that can be small-molecule drugs that employ straightforward médicinal chemistry processes.
The administration of the formulations of the présent disclosure can be performed in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intracerebrally, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, intrathecally, vaginally, rectally, intraocularly, or in any other acceptable manner. The formulations can be administered continuously by infusion, although bolus injection is acceptable, using techniques known in the art, such as pumps (e.g., subcutaneous osmotic pumps) or implantation. In some instances the formulations can be directly applied as a solution or spray.
An example of a pharmaceutical composition is a solution designed for parentéral administration. Although in many cases pharmaceutical solution formulations are provided in liquid form, appropriate for immédiate use, such parentéral formulations can also be provided in frozen or in lyophilized form. In the former case, the composition must be thawed prior to use. The latter form is often used to enhance the stability of the active compound contained in the composition under a wider variety of storage conditions, as it is recognized by those of ordinary skill in the art that lyophilized préparations are generally more stable than their liquid counterparts. Such lyophilized préparations are reconstituted prior to use by the addition of one or more suitable pharmaceutically acceptable diluents such as, without limitation, stérile water for injection or stérile physiological saline solution.
Parenterals can be prepared for storage as lyophilized formulations or aqueous solutions by mixing, as appropriate, the compound having the desired degree of purity with one or more pharmaceutically acceptable carriers, excipients or stabilizers typically employed in the art (ail of which are termed excipients), for example buffering agents, stabilizing agents, preservatives, isotonifiers, non-ionic détergents, antioxidants and/or other miscellaneous additives.
Buffering agents help to maintain the pH in the range which approximates physiological conditions. They are typically présent at a concentration ranging from 2 mM to 50 mM. Suitable buffering agents for use with the présent disclosure include both organic and inorganic acids and salts thereof such as citrate buffers (e.g., monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture, etc.), succinate buffers (e.g., succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, fumaric acid-disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture, etc.), gluconate buffers (e.g., gluconic acid-sodium glyconate mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium glyuconate mixture, etc.), oxalate buffer (e.g., oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture, etc.), lactate buffers (e.g., lactic acid-sodium lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture, etc.) and acetate buffers (e.g., acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture, etc.). Additional possibilities are phosphate buffers, histidine buffers and trimethylamine salts such as Tris.
Preservatives can be added to retard microbial growth, and are typically added in amounts of 0.2%-1% (w/v). Suitable preservatives for use with the présent disclosure include, without limitation, phénol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides (e.g., benzalkonium chloride, bromide or iodide), hexaméthonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol and 3-pentanol.
Isotonicifiers can be added to ensure isotonicity of liquid compositions and include, without limitation, polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol. Polyhydric alcohols can be présent in an amount between 0.1% and 25% by weight, typically 1% to 5%, taking into account the relative amounts of the other ingrédients.
Stabilizers refer to a broad category of excipients which can range in function from a bulking agent to an additive which solubilizes the therapeutic agent or helps to prevent dénaturation or adhérence to the container wall. Typical stabilizers can be polyhydric sugar alcohols (enumerated above); amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, etc., organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinisitol, galactitol, glycerol and the like, including cyclitols such as inositol; polyethylene glycol; amino acid polymers; sulfur-containing reducing agents, such as urea, glutathione, thioctic acid, sodium thioglycolate, thioglycerol, alpha-monothioglycerol and sodium thiosulfate; low molecular weight polypeptides (i.e., <10 residues); proteins such as human sérum albumin, bovine sérum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides such as xylose, mannose, fructose and glucose; disaccharides such as lactose, maltose and sucrose; trisaccharides such as raffinose, and polysaccharides such as dextran. Stabilizers are typically présent in the range of from 0.1 to 10,000 parts by weight based on the active compound weight.
Additional miscellaneous excipients include fillers (e.g., starch), chelating agents (e.g., EDTA), antioxidants (e.g., ascorbic acid, méthionine, vitamin E) and cosolvents.
The active ingrédient can also be entrapped in microcapsules prepared, for example, by coascervation techniques or by interfacial polymerization, for example hydroxymethylcellulose, gelatin or poly-(methylmethacylate) microcapsules, in colloïdal drug delivery Systems (for example liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington, The Science and Practice of Pharmacy, 21st Ed., published by Lippincott Williams & Wilkins, A Wolters Kluwer Company, 2005, the teachings of which are incorporated by reference herein.
Parentéral formulations to be used for in vivo administration generally are stérile. This is readily accomplished, for example, by filtration through stérile filtration membranes.
Suitable examples of sustained-release préparations include semi-permeable matrices of solid hydrophobie polymers containing the compound or composition, the matrices having a suitable form such as a film or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate) or poly(vinylalcohol)), polylactides, copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylenevinyl acetate, degradable lactic acid-glycolic acid copolymers such as the PROLEASE® technology (Alkermes, Cambridge, Massachusetts) or LUPRON DEPOT® (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate; Abbott Laboratories, Abbott Park, Illinois), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molécules for long periods such as up to or over 100 days, certain hydrogels release compounds for shorter time periods.
Oral administration of the compounds and compositions is one intended practice of the disclosure. For oral administration, the pharmaceutical composition can be in solid or liquid form, e.g., in the form of a capsule, tablet, powder, granule, suspension, émulsion or solution. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingrédient. A suitable daily dose for a human or other vertebrate can vary widely depending on the condition of the patient and other factors, but can be determined by persons of ordinary skill in the art using routine methods.
In solid dosage forms, the active compound can be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances, e.g., lubricating agents such as magnésium stéarate. In the case of capsules, tablets and pills, the dosage forms can also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
The compounds or compositions can be admixed with adjuvants such as lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnésium stéarate, magnésium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinyl-pyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, they can be dissolved in saline, water, polyethylene glycol, propylene glycol, éthanol, oils (such as corn oil, peanut oil, cottonseed oil or sesame oil), tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are known in the pharmaceutical art. The carrier or diluent can include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials known in the art.
The présent disclosure further includes the use and application of the compounds, compositions and methods herein in vitro in a number of applications including but not limited to developing thérapies and vaccines against viral infections, research in modulation of the innate immune response in eukaryotic cells, etc. The compounds, compositions and methods of the présent disclosure can also be used in animal models. The results of such in vitro and animal in vivo uses of the compounds, compositions and methods of the présent disclosure can, for example, inform their in vivo use in humans, or they can be valuable independent of any human therapeutic or prophylactic use.
Examples
The Examples below describe the antiviral and pharmacological properties of the disclosed compounds. The Examples are included to demonstrate particular embodiments of the disclosure. It should be appreciated by those of ordinary skill in the art that the techniques disclosed in the Examples represent techniques and compositions discovered by the inventors to function well in the practice of the disclosure, and thus can be considered to constitute preferred modes for its practice. However, those of ordinary skill in the art should, in light of the présent disclosure, appreciate that many changes can be made in the spécifie embodiments which are disclosed and still obtain a like or similar resuit without departing from the spirit and scope of the disclosure. For example, the Examples below provide in vitro methods for testing the compounds of the disclosure. Other in vitro virus infection models include but are not limited to flaviviruses such as bovine diarrheal virus, West Nile Virus, and GBV-C virus, other RNA viruses such as respiratory syncytial virus, and the HCV replicon Systems. Furthermore, any appropriate cultured cell competent for viral réplication can be utilized in the antiviral assays.
Example 1. Biological activity of Kl N1000
Luciferase assay to identify active compounds. Cultured human cells that were stably transfected with a luciferase reporter gene coupled with a RIG-I signaling pathway responsive promoter (ΙΡΝβ, ISG56, or ISG54 promoter) were seeded and allowed to grow overnight. The compound “KIN1000” was then added and cells were grown in the presence of KIN1000 for 1820 hours. Steady-GIo luciferase substrate (Promega) was added and luminescence was read on a luminometer (Berthold).
Figure 1A shows that KIN1000 as described herein was validated by demonstrating dosedependent induction of the luciferase reporter gene coupled to the promoters for ΙΡΝβ (ΊΡΝβLUC,” left), ISG56 (“ISG56-LUC,” center), and ISG54 (“ISG54-LUC,” right). Additionally, KIN1000 did not induce a nonspecific promoter (β-actin-LUC, Figure 1B).
MTS assay to détermine cytotoxicity. Cultured human HeLa cells were treated with increasing amounts of compound or équivalent amounts of DMSO diluted in media for 48 hours to see their effect on cell viability. The proportion of viable cells was calculated using a cell viability assay that measures conversion of a tétrazolium compound [3-(4,5-dimethyl-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner sait; or MTS] to a colored formazan compound in live cells.
The conversion of MTS to formazan was detected in a 96-well microtiter plate reader, and the resulting optical densities plotted directly to estimate cell viability. Cell Titer One (Promega) was the one-step reagent used, as manufacturées protocol suggested, and cells were incubated for three hours in the presence of reagent before optical density (O.D.) reading was done. Compounds were diluted to final concentrations of 0, 1, 5, 10, and 20 μΜ in media containing 0.5% DMSO. Négative control wells contained no compound, and positive control for cytotoxicity was examined using 10% DMSO. Each Kl N1000 concentration and control was done in triplicate wells. Kl N1000 showed no cytotoxicity to multiple cell types (MTS assay, Figure 1C).
Immunofluorescent cytochemistry assay to détermine IRF-3 activation and translocation to the nucléus. The induction of ISG expression mediated by RIG-I is conferred by phosphorylation, dimerization, and nuclear translocation of the IRF-3 transcription factor. Cultured human HeLa cells were treated with increasing amounts of compound or équivalent amounts of DMSO diluted in media for 20 hours. Positive control wells were infected with 100 HA/mL Sendai virus for an équivalent time period. IRF-3 was detected using polyclonal rabbit sérum spécifie to IRF-3 and a secondary antibody conjugated to DyLight® (Pierce Biotechnology, Inc., Rockford, IL) 488. KIN1000 shows a dose dépendent increase in nuclearcytoplasmic différence for IRF-3 (Figure 2A).
Immunofluorescent cytochemistry assay to détermine NFkB activation. The innate immune response dépendent on RIG-I also activâtes the NFkB transcription factor and thus increases nuclear levels. Cultured human HeLa cells were treated with increasing amounts of compound or équivalent amounts of DMSO diluted in media for 20 hours. Positive control wells were infected with 100 HA/mL Sendai virus for an équivalent time period. NFkB was detected using monoclonal mouse antibody spécifie to the p65 subunit of NFkB and a secondary antibody conjugated to DyLight 488.
Quantification of immunofluorescent assays. 96-well plates containing cultured human cells treated with compound and stained for either IRF-3 or NFkB were scanned and quantified using the ArrayScan® instrument and software (Cellomics). Activation of transcription factor was evidenced by increased nuclear intensity normalized for cytoplasmic intensity, or nuclearcytoplasmic différence. ΚΙΝ1000 shows a dose dépendent increase in nuclear-cytoplasmic différence for NFkB (Figure 2B).
Other compounds as described herein likewise can be evaluated by the methods described in this example, and other cell types can also be used.
Example 2. Antmral activity of KIN1000 against influenza WSN strain
MRC5 cells were treated with increasing amounts of Kl N1000 12-24 hours prior to infection by influenza virus. The number of infected cells 24 hours after introduction of virus was then quantified by an immunofluorescent assay of viral protein in cells. The KIN1000 compound disclosed herein demonstrated efficient activity against influenza virus strain WSN. Figure 3 shows that MRC5 cells treated with increasing amounts of KIN1000 showed a dose-dependent decrease in infection by influenza virus.
Example 3. Ex vivo immune stimulatory activity of KIN1000
The activity of KIN1000 in primary immune cells was assayed to détermine whether KIN1000 stimulâtes immune responses. Cultured human primary dendritic cells were treated with 0, 1, or 10 μΜ of Kl N1000 for 24 hours. Supernatant from treated wells was isolated and tested for levels of cytokine protein. Cytokines were detected using spécifie antibodies conjugated to magnetic beads and a secondary antibody that reacts with Streptavidin/Phycoerythrin to produce a fluorescent signal. The bound beads were detected and quantified using the Magpix® (LuminexCorp.) instrument, although similar techniques as are known in the art may be used to measure fluorescent protein production, such as for example an ELISA.
KIN1000 was shown to induce expression of the chemokines IL-8, MCP-1, MIP-1a and ΜΙΡ-1β by dendritic cells (Figure 4).
Other cells from which cytokine sécrétion can be measured include, for example but without limitation, human peripheral blood mononuclear cells, human macrophages, mouse macrophages, mouse splénocytes, rat thymocytes, and rat splénocytes.
Example 4. antiviral activity and pharmacological properties using structure-activity RELATIONSHIP (SAR) STUDIES
This Example describes optimization of compounds for antiviral action. First, a small analog dérivative set is used to define a structural class. The active analogs that are identified in this first stage are then used to define a subset of structural classes of interest for further optimization (Stage 2).
Stage 2, dérivative expansion. Stage 2 focuses on creating structural diversity and evaluating core variants. Structural dérivatives are tested for biological activity in the IRF-3 translocation assay, antiviral activity, and cytotoxicity in one or more cell lines or peripheral blood mononuclear cells. Optimized molécules that show improved efficacy and low cytotoxicity are further characterized by additional measures of in vitro toxicology and absorption, distribution, metabolism, and élimination (ADME). Their mechanism of action and breadth of antiviral activity are also studied.
Chemical design in SAR studies. To design analog structures, the drug-like properties, metabolic lability, and toxic potential of the lead compounds are analyzed. Drug-like properties, as measured by Lipinski’s Rules, and related physiochemical properties are primary indicators of bioavailability. Structural features that suggest metabolic and toxicological liabilities may indicate limited stability, reduced half-life, reactive intermediates, or idiosyncratic toxicity and will therefore be removed. A 5- to 10-compound analog set is constructed to remove or alter chemically reactive or metabolically susceptible structural features, thereby developing a preliminary SAR.
Compounds are tested for in vitro antiviral activity against HCV 2A, respiratory syncytial virus, dengue virus type 2, and influenza A virus strains. Viral protein and RNA levels are assessed following drug treatment using the assays described herein.
Following several itérative rounds of SAR, compounds are selected for characterization of their in vitro toxicological and ADME properties and for further mechanistic study. The SAR studies are designed to provide lead compounds with picomolar to nanomolar potency, which is adéquate to support preclinical development.
In vitro pharmacology. In vitro pharmacology studies are performed to measure performance of the most promising analogs in one or more assays of intestinal permeability, metabolic stability and toxicity. Key in vitro characterization studies can include plasma protein binding; sérum, plasma, and whole-blood stability in human and model organisme; intestinal permeability; intrinsic clearance; human Ether-à-go-go (hERG) channel inhibition; and genotoxicity.
For each analog, an HPLC- and/or HPLC-mass spectrometry-based analytical method is used to evaluate drug and métabolite concentrations in various test Systems. Although the spécifie analytical method is optimized for each molécule, reverse-phase chromatography can be used alone or in combination with quadrupole mass spectrometry to characterize the identity and purity of several of the lead molécules. Initially, drug stability over time in increasing concentrations of sérum, plasma, and whole blood from mammalian species (such as mouse, cynomolgus macaque, and human) is evaluated by HPLC, and a half-life is determined.
Prominent métabolites characterized by mass spectrometry. Human plasma protein binding are evaluated by partition analysis using equilibrium dialysis. For intestinal permeability modeling, apical-to-basolateral flux is assessed in the human épithélial cell line TC7. Hepatic clearance is estimated for a subset of the most promising analogs by measuring the rate of disappearance of the parent compound during incubation in human liver microsomes. As above, spécifie métabolites can be isolated and characterized.
In vitro toxicology. In vitro toxicology studies are performed to evaluate the potential cardiac and genetic toxicity of lead analogs. Automated patch-clamp is used to assess the impact of each compound on hERG channel currents in a recombinant Chinese hamster ovary (CHO) cell line transgenically expressing the human Kv11.1 gene. Concentrations up to the lesser of 30 times the maximum sérum concentration or the limit of solubility of each compound are evaluated in order to détermine an IC50 for the molécule on the hERG channel. A subset of compounds is evaluated over a range of concentrations for their ability to induce mutation reversion in Salmonella typhimurium strains TA98 and TA100 or to promote micronucleus formation in CHO cells in culture.
EXAMPLE 5. ACTIVATION OF GENE EXPRESSION BY KIN1000 AND DERIVATIVE COMPOUNDS
Gene expression in HeLa cells. Cultured human cells were treated with 20μΜ, 10μΜ, 5μΜ of compound or a DMSO control and incubated for up to 24 hours. Cells were harvested and RNA was isolated using the QIAshredder columns and RNeasy Mini Kit (Qiagen) according to manufacturer instructions. Reverse transcription was performed and the cDNA template was used for quantitative real-time PCR. PCR reactions were performed using commercially available, validated TaqMan gene expression assays (Applied Biosystems/Life Technologies) according to manufacturer instructions. Gene expression levels were measured using a relative expression analysis (AACt).
Gene expression in PH5CH8 cells. Cultured human cells were treated with 10uM, 5uM, 1uM or a DMSO control and incubated for up to 24 hours. Cells were harvested and RNA was isolated using the QIAshredder columns and RNeasy Mini Kit (Qiagen) according to manufacturer instructions. Reverse transcription was performed and the cDNA template was used for quantitative real-time PCR. PCR reactions were performed using commercially available, validated TaqMan gene expression assays (Applied Biosystems/Life Technologies) according to manufacturer instructions. Gene expression levels were measured using a relative expression analysis (AACt).
Gene expression in HUVEC primary cells. Cells were thawed and seeded in 6-well plates at 2.4x104 cells per well and allowed to grow to 80% confluence, typically 5 days in culture with fresh media replaced every 48 hours. Compound was added at 10μΜ, 1μΜ or a DMSO control and incubated for up to 24 hours. Cells were harvested and RNA was isolated using the QIAshredder columns and RNeasy Mini Kit (Qiagen) according to manufacturer instructions. Reverse transcription was performed and the cDNA template was used for quantitative real-time PCR. PCR reactions were performed using commercially available, validated TaqMan gene expression assays (Applied Biosystems/Life Technologies) according to manufacturer instructions. Gene expression levels were measured using a relative expression analysis (AACt).
Figure 5 shows induction of gene expression by KIN1000 and its dérivative compound KIN1148. Figure 5A shows gene expression levels of IFIT2 (left) and OAS1 (right) in HeLa cells over time from 4-24 hours post treatment with 10μΜ KIN1000 (grey) or 10μΜ KIN1148 (black). Figure 5B shows gene expression levels of IFIT2 in PH5CH8 cells (left) treated with KIN1000 (solid grey bars) or KIN1148 (solid black bars), and in HeLa cells (right) treated with KIN1000 (grey striped bars) or KIN1148 (black checked bars). In each test group, the three vertical bars represent 5, 10, and 20 μΜ compound (KIN1000 or KIN1148), respectively. Figure 5C shows gene expression levels of IFIT2 (left), OAS1 (center), and MxA (right) in primary HUVEC cells that were treated with 1μΜ KIN1000 (grey) or 1μΜ KIN1148 (black). The différence in axis scaling demonstrates that compounds are more active in a primary cell type. These data demonstrate that compounds are active in cells by inducing responsive gene expression.
Gene expression can be similarly assayed in cell types that include, without limitation: primary blood mononuclear cells, human macrophages, THP-1 cells, Huh 7 cells, A549 cells, MRC5 cells, rat splénocytes, rat thymocytes, mouse macrophages, mouse splénocytes, and mouse thymocytes. Expression of other genes of interest can be assayed as described herein.
Example 6. Antiviral activity of KIN1000 against various viruses
Antiviral action in cell culture infection models. To further characterize the breadth of antiviral activity of optimized molécules, cell culture infection models are used to analyze different viruses, including but not limited to different strains of influenza virus, HCV, Dengue virus, RSV, and West Nile virus (WNV), an emerging public health concern. The studies include treating cells with compound 2-24 hours prior to infection or treating cells up to 8 hours after infection. Virus production and cellular ISG expression are assessed over a time course to analyze antiviral effects of représentative compounds from lead structural classes. ΙΡΝβ treatment is used as a positive control.
Virus production is measured by focus-forming or plaque assay. In parallel experiments, viral RNA and cellular ISG expression are measured by qPCR and immunoblot analyses. These experiments are designed to validate compound signaling actions during virus infection, and assess compound actions to direct innate immune antiviral programs against various strains of viruses and in the setting of virus countermeasures. Detailed dose-response analyses of each compound are conducted in each virus infection System to détermine the effective dose that suppresses virus production by 50% (IC50) and 90% (IC90) as compared with control cells for both the pre-treatment and post-treatment infection models.
Table 2. Virus Systems and study design for antiviral analysis of lead compounds
Virus | Virus Strain | Study Design |
HCV | H77 (génotype 1a) JFH1 (génotype 2a) | Assays Plaque or focus forming assays (infectious virus) qPCR (RNA levels) Immunoblot and ELISA (protein levels) Study Design Compound treatment of cells preand post-infection Détermine EC50 and ECgo Inhibition of viral life cycle |
FLU | High pathogenicity in mice A/PR/8/34 (H1N1 mouse-adapted virus) A/WSN/33 (H1N1 mouse-adapted neurovirulent virus) Low pathogenicity in mice A/Texas/36/91 (H1N1 circulating virus) A/Udorn/72 (H3N2) | |
WNV | TX02 (lineage 1) MAD78 (lineage 2) |
EXAMPLE 7. Activity of KIN1000 and dérivative compounds against respiratory
SYNCYTIAL VIRUS.
HeLa cells were seeded the previous day in 6-well plates at 4x105 cells per well. The next day, the media was replaced with RSV in media without FBS at an MOI of 0.1. Virus binding occurred at 37°C for 2 hours. After 2 hours the cells were washed with warm complété media and replaced with media containing drug at varying concentrations of 10μΜ, 5μΜ, 1μΜ or a DMSO control. Cells were placed in a 37°C incubatorfor 48 hours.
For virus détection and titration, HeLa cells were seeded in 96-well plates at 8x103 cells per well 24hrs prior to collecting virus supernatant. After the 48 hour incubation period, the virus supernatant from the infected plate was harvested and used to infect these cells at a 1/10 final dilution. Cells were placed in a 37°C incubator for 24 hours.
hours after infection, cells were washed twice with PBS and fixed with methanol/acetone solution. After fixing the cells were washed twice with PBS and replaced with blocking buffer (10% horse sérum, 1g/mL BSA and 0.1% Triton-100X in PBS) for 1 hour. The blocking buffer is replaced with binding buffer containing a 1/2000 dilution of primary antibody for 2 hours at room température. The primary antibody was a mouse monoclonal antibody against RSV. The cells were washed twice with PBS and replaced with binding buffer containing 1/3000 dilution of the Alexa Fluor-488 goat anti-mouse secondary antibody and a Hoechst nuclear stain for 1 hour at room température. The cells were washed twice with PBS and PBS is added to ail wells. The 96-well plate is sealed and fluorescence activity associated with virus infectivity was determined by immunofluorescent assay using the Array Scan instrument (Thermo-Fischer).
Figure 6 shows experiments performed using the protocol of the Example, demonstrating the antiviral activity of KIN1000 and KIN1148 against respiratory syncytial virus. Figure 6A shows that HeLa cells treated with increasing amount of KIN1000 and KIN1148 showed dosedependent decrease in infection by RSV. Figure 6B shows that KIN1148 showed antiviral activity against RSV when drug is added up to 24 hours prior to infection.
Treatment with compounds prior to infection. In variations of this method, the compounds are added at varying time points prior to infection with virus. Virus détection and titration is conducted as described.
Analog testing and SAR studies. Antiviral activity against RSV was used as a criterion to measure activity of structural dérivatives of KIN1000. Table 3 shows select structural dérivatives of KIN1000 that demonstrated antiviral activity against RSV. Compared to KIN1000 parent compound, these analogs showed varying levels of antiviral activity against RSV. +++ = greater than 70% inhibition of infection, ++ = greater than 50% inhibition, + = greater than 30% inhibition, - = less than 30% inhibition.
TABLE 3
R2
I
KIN | R3 | RI | 10 uM | 5uM | 1 uM | |
1000 | H | ++ | + | - | ||
1014 | H | + | - | - | ||
1034 | O ω | H | - | + | - | |
1069 | Cl CI^^V | H | H | ++ | + | - |
1072 | H | H | ++ | - | - | |
1075 | + | - | - | |||
1148 | H | H | +++ | ++ | - | |
1169 | H \ ^hk . 1 | H | +++ | ++ | - | |
1170 | H J N O^J | H | ++ | - | - | |
1203 | /T”\ z y | H | H | +++ | - | - |
EXAMPLE 8. Activity of KIN1000 and dérivative compounds against influenza A/Udorn/72 virus
Influenza A/Udorn/72 infection of H292 cells. ,2x106 H292 cells in RPMI1640+10%FCS were treated with 2μΜ KIN1148 in a final concentration of 0.5% DMSO for 6 hours. Compoundcontaining media was aspirated and replaced with 1X MEM containing A/Udorn/72 at an MOI of 0.1 and placed at 37°C in a CO2 incubator. Two hours post infection, virus-containing media was aspirated and replaced with 1X MEM containing 1ug/mL TPCK-treated Trypsin, 2μΜ KIN1148, 0.5% DMSO. Cells were placed in 37°C CO2 incubator for 18 hours. After 20 hours post-infection, virus supernatants were collected and titred on MDCK cells.
Influenza A/Udorn/72 infection of HEK293 cells. 5x105 HEK293 cells were infected with A/Udorn/72 at an MOI of 0.2 in 1X MEM. After 2 hours post-infection, virus-containing media was aspirated and replaced with 1X MEM containing 1pg/mL TPCK-treated Trypsin, 10μΜ KIN1148, 0.5% DMSO. Cells were returned to 37°C, CO2 incubator for 18 hours. After 20 hours post-infection, virus supernatants were collected and titred on MDCK cells.
Titre in MDCK cells. 10pL of infected supernatant was added to 2x106 MDCK cells in the presence of 2pg/mL TPCK-trypsin and placed in a 37°C CO2 incubator. After 8 hours, supernatant was removed and cells were fixed and stained with FITC-conjugated antibody spécifie for Influenza NP protein. Number of foci was quantitated using the ArrayScan instrument and software (Cellomics).
Figure 7 shows antiviral activity of KIN1148 against Influenza A virus Udorn/72. H292 cells (left) and HEK293 cells (right) treated with 2uM (H292) or 10uM (HEK293) of KIN1148 showed decrease in infection by virus.
EXAMPLE 9. ACTIVITY OF KIN1000 AND DERIVATIVE COMPOUNDS AGAINST DENGUE VIRUS
Huh 7 cells were seeded the previous day in 6-well plates with 4x105 cells per well. The next day, the media was replaced with Dengue virus type 2 in media without FBS at an MOI of 0.25. Virus binding occurred at 4°C for 1 hour. After 1 hour the cells were washed with warm complété media and replaced with media containing KIN1148 at varying concentrations of 10uM, 5uM, 1uM or a DMSO control. Cells were placed in a 37°C incubator for 48 hours.
Titre in Vero cells. Vero cells were seeded in 96-well plates at 8x103 cells per well 24hrs prior to collecting virus supernatant. After 48hrs, the virus supernatant was harvested and used to infect Vero cells at a 1/100 final dilution.
hrs after infection, Vero cells were washed 2x with PBS and fixed with methanol/acetone for 15mins. After fixing the cells were wash 2x with PBS and replaced with blocking buffer for 30-45 mins. The blocking buffer was replaced with binding buffer containing a 1/2000 dilution of primary monoclonal antibody targeting the Envelope protein for 2hrs. After 2hrs, the cells were washed 2x with PBS and replaced with binding buffer containing 1/3000 dilution of the Alexa Fluor-488 goat anti-mouse secondary antibody and a Hoechst nuclear stain for 45mins. After 45 mins cells were washed 2x with PBS and PBS was added to ail the well. The 96-well plate was sealed and fluorescence activity associated with virus infectivity was determined by IF using the ArrayScan instrument and software (Cellomics).
Figure 8 shows the results of experiments performed using the protocol of this Example, demonstrating the antiviral activity of KIN1148 against Dengue virus type 2. Huh 7 cells treated with increasing amounts of KIN1148 showed dose-dependent decrease in infection by virus.
EXAMPLE 10. Activity of KIN1000 and dérivative compounds against Hepatitis B virus HepAD38 cells (Hep 2 cells expressing a regulated HBV genome) were grown for 72 hours in the presence of compound (concentrations 1-10 μΜ in 0.5% DMSO media). HepAD38 cells that do not express HBV were used as a négative control. Following 72 hours of treatment 100 pl of media was used in an ELISA to measure HBV surface antigen. The amount of HBV surface antigen produced by the cells was measured in the supernatants by ELISA commercially available HBV sAg ELISA from Creative Diagnostics, NJ.
Figure 9 shows the results of experiments performed using the protocol of this Example, demonstrating the antiviral activity of ΚΙΝ1148 against Hepatitis B virus. HepAD38 cells treated with increasing amounts of ΚΙΝ1148 showed dose-dependent decrease in supernatant levels of virus.
Example 11. In vivo pharmacokinetic, toxicological, and antiviral properties of OPTIMIZED DRUG LEADS IN RELEVANT PRECLINICAL ANIMAL MODELS
Preclinical pharmacokinetic and tolerability profiling. The in vivo pharmacokinetic (PK) profile and tolerability/toxicity of Kl N1000 and related compounds are evaluated in order to conduct further characterization of their antiviral activity in animal models of influenza virus and WNV infection. Mouse is the chosen test species for these studies since it is the most commonly used rodent model of WNV and influenza.
A reverse-phase, HPLC-MS/MS détection method is used for measuring the concentration of each compound in mouse plasma. Prior to PK profiling, an initial oral and intravenous formulation for each compound is developed using a limited formulation component screen that is largely focused on maximizing aqueous solubility and stability over a small number of storage conditions. Any of the analytical methods as are known in the art can be used to measure formulation performance. A formulation is developed for each compound following a three tiered strategy:
Tier 1 : pH (pH 3 to 9), buffer, and osmolality adjustment
Tier 2: addition of éthanol (<10%), propylene glycol (<40%), or polyethylene glycol (PEG) 300 or 400 (<60%) co-solvents to enhance solubility
Tier 3: addition of A/-/V-dimethylacetamide (DMA, <30%), /V-methyl-2-pyrrolidone (NMP, <20%), and/or dimethyl sulfoxide (DMSO, <20%) co-solvents or the cyclodextrins (<40%) as needed to further improve solubility.
For compounds that demonstrate adéquate performance in in vitro antiviral, mechanistic, ADME, and toxicology studies, a preliminary mouse PK study is performed. See Table 3. Each compound is administered as a single dose to animais by oral gavage (<10 ml/kg) or i.v. bolus injection (<5 ml/kg) after an overnight fast. Multiple animais are dosed for each dosing group such that 3 animais can be sampled at each time point. Blood samples are collected by retroorbital sinus prior to dosing and at 5, 15, and 30 minutes, and 1, 2, 4, 8, and 24 hours postdosing. Drug concentrations are measured according to the previously developed bioanalytical method. Pharmacokinetic parameters are evaluated using the WinNonlin software.
Table 4
Study | Experimental design | Route of administration | Outcomes |
Mouse PK | Single dose pharmacokinetic study | IV and Oral | Oral bioavailability, Cmax, t/2, Cl, Vd, AUCq-24,0- CO |
Mouse tolerability | Phase 1: ascending dose tolerability and MTD détermination; Phase 2: placebo controlled 7-day toxicity at MTD | Oral | MTD, acute toxicity, hematology, sérum chemistry, gross pathology |
Based upon performance in exploratory PK studies, compounds are further evaluated for preliminary tolerability and toxicity in mice prior to their characterization in antiviral models. Tolerability studies are performed in two stages: an initial dose escalation stage (up to 5 doses, each separated by a 5-day washout period) to détermine the maximum tolerable dose (MTD, Phase 1), followed by seven daily administrations of the MTD to evaluate acute toxicity (Stage 2). See Table 3. Ail doses are administered by oral gavage. In an exemplary experiment, five animais of each sex are placed on-study in stage 1 and 15 animais per sex per dosing group in Stage 2. Study endpoints include a détermination of the MTD, physical examination, clinical observations, hematology, sérum chemistry and animal bodyweights. Gross pathology is performed on ail animais whether found dead, euthanized in extremis, or at the intended conclusion of the experiment. The toxicology studies are primarily exploratory in nature and intended to identify early toxicological endpoints, and drive sélection of lead candidates for antiviral animal models.
Table 5. In vivo studies of compound actions against WNV and influenza virus_________________
Experiment | Analysis | Goal | Exemplary No. of Mice* |
Effective compound dose détermination | Viral burden analysis in sérum | Define in vivo EC5o and EC90 | 238 |
Viral pathogenesis study 1 : EC50 and EC90 T reatment | Time to moribund State, clinical scoring for pathologie signs of infection | Define compound action toward limiting viral pathogenesis | 739 |
Viral pathogenesis study 2: EC50 and EC90 treatment and time course analysis | Viral burden analysis in sérum and various target organs | Define compound action toward limiting virus réplication and spread | 1056 |
Viral pathogenesis study 3: (neuroinvasion model) EC50 and EC90 treatment | Time to moribund State, clinical scoring for pathologie signs of infection | Define compound action toward limiting viral pathogenesis in the CNS | 370 |
*Numbers reflect an average of at least two itérations of each experiment
Evaluation of antiviral properties and immune protection using mouse infection models. Optimized compounds are selected based on compound pharmacokinetic, antiviral, and innate immune actions for further évaluation in preclinical mouse models of infection. See Table 4. Innate immune actions of the compounds are measured, and their ability to protect mice from WNV and influenza virus challenge is assessed. For the WNV infection model, subcutaneous footpad infection of wild-type C57BI/6 mice with the virulent lineage 1 strain of WNV (WNV-TX) are performed. Non-surgical trachéal instillation is performed for influenza virus strains A/PR/8/34, A/WSN/33, and A/Udorn/72.
The influenza virus strains used for certain experiments are of two different subtypes (H1N1 and H3N2) and exhibit varying pathogenic properties and clinical présentations in C57BI/6 mice. Mice are monitored for morbidity and mortality over a range of challenge doses (such as, 10 to 1,000 pfu of virus) either alone or in combination with compound treatment beginning 12 hours before or 24 hours after infection and continuing daily subject to the determined plasma half-life of the drug. Compound dose-response analysis and infection time course studies are conducted to evaluate compound efficacy to: 1) limit sérum viral load, 2) limit virus réplication and spread in target organs, and 3) protect against viral pathogenesis.
For WNV, in addition to sérum, viral burden is assessed in lymph nodes, spleen, and brain; for influenza virus, viral burden is assessed in heart, lung, kidney, liver, and brain. Incorporated in the design of these experiments is the détermination of an effective dose for 50% and 90% suppression of sérum viral load (ED50 and ED90) by each compound after a standard challenge of 100 pfu of WNV-TX or 1,000 pfu of influenza virus. Sérum viral loads are determined by qPCR of viral RNA at 24-hour intervals following compound treatment. The compound actions are tested at the ED50 and ED90 toward limiting WNV pathogenesis in the cérébral nervous System using a WNV neuroinvasion model of infection.
Mice are monitored for morbidity and mortality after standard intracranial challenge of 1 pfu of WNV-MAD, either alone or in combination with compound treatment beginning 24 hours after infection.
Example 12. Antiviral activity of KIN1000 and dérivative compounds in vivo
Evaluation of antiviral properties of Kl N1000 and dérivative compounds using mouse infection models. Up to 5 of the most promising compounds will be selected for further évaluation in preclinical mouse models of infection with Influenza and/or respiratory syncytial virus. Table 6 lists the nonclinical studies to measure antiviral efficacy of Kl N1000 and dérivative compounds.
Table 6. Nonclinical studies to measure drug concentration and antiviral efficacy in vivo
Study | Experimental design | Route Admi. | No. Cpds. | No. Animais | Outcomes |
Mouse dosing | Drug measured in blood at 3 dose levels; 2, 8, 24 hours post treatment | Oral/IP | <5 | 120 | Drug concentration in blood; HPLC reverse phase |
Mouse Influenza Model | Trachéal instillation of A/WSN/33 or A/Udorn/72; drug treatment at 2 doses w/ placebo | Oral/IP | <5 | 480 | Mortality, viral titer in serum/target organs, body temp., bodyweight, clin, obs., cytokine levels |
Mouse RSV Model | Trachéal instillation of RSV A2 Long strain; drug treatment at 2 doses w/ placebo control | Oral/IP | <5 | 240 | Mortality; bodyweight; target organ viral titer; innate immune gene expression; markers of inflammation |
Mouse influenza model. We will perform non-surgical trachéal instillation of influenza virus strains A/WSN/33 and A/Udorn/72. These influenza virus strains are two different subtypes (H1N1 and H3N2) and exhibit varying pathogenic properties and clinical présentations in C57BI/6 mice. Lead dérivatives of the KIN1000 family of compounds will be administered daily by oral gavage or IP administration over the entire course of infection (typically 2 weeks) at 2 dose levels plus a placebo control group. Five animais per sex and per group will be evaluated for endpoints, including but not limited to daily clinical observations, mortality, body weight, and body température. Three animais per sex will be used to measure virus titer in sérum, heart, lung, kidney, liver, and brain. Cytokine expression at various time points during infection in compound-treated versus control animais will be assayed.
Mouse RSV model. We will perform non-surgical trachéal instillation of respiratory syncytial virus A2 long strain. BALB-c mice will be infected at a dose of RSV A2 virus that does not cause cytopathic effects followed by daily oral or IP administration of compound at 2 dose levels or a placebo control for up to 21 days. Mice will be monitored as described above, including inspection for morbidity and mortality, viral titer in sérum and blood, cytokine sécrétion, increased immune cell populations, and innate immune gene expression.
Example 13. Adjuvant activity of KIN1000 and dérivative compounds in vivo
To characterize the breadth of adjuvant activity of Kl N1000 and related compounds, in vivo animal models of vaccination and vaccination plus protection are used. The studies include priming animais including but not limited to rats and mice with compound alone or in combination with an antigen and then assessing the adjuvant effect.
Adjuvant effect is measured by assays for modified, enhanced immune humoral and cellular responses. Humoral responses are assessed over time at discrète times post vaccination and/or boosting by collecting blood for sera and determining relative concentrations of antibody classes (IgM, IgG, IgA or IgE) and/or isotypes including lgG1, lgG2a, lgG2b, lgG2c, lgG3 for IgG antibodies. Moreover, affinity and avidity of the generated antibodies is also determined. In instances in which the vaccine préparation includes a combination of compound and antigen, the neutralizing activity of the generated antibodies is also determined.
Cellular mediated immune responses induced by the compounds are measured by established methods in the field including ex vivo stimulation of peripheral blood mononuclear cells, lymph nodes, splénocytes or other secondary lymphoid organs with the antigen and measurement of cytokine or chemokine production in the supernatant at several times thereafter. Cytokines measured include Th1 type of cytokines including but not limited to IFN gamma and TNF alpha, Th2 type cytokines including but not limited to IL-4, IL-10, IL-5 and IL-13 and Th17 cytokines including but not limited to IL-17, IL-21 and IL-23. Chemokines elicited by the compounds are also measured including but not limited to RANTES, IP-10, MIP1a, MIP1b, and IL-8. T cell antigen spécifie production of cytokines can also be measured by intracellular cytokine staining with fluorescently labeled spécifie antibodies and flow cytometry or by ELISPOT. Both CD4+ ad CD8+ T cell populations are studied.
Measurement of adjuvant activity at the cellular level is also determined by immunophenotyping of surface markers of activation by flow cytometry. CD8 T cell antigen-specific responses are also evaluated by intracellular cytokine staining of perforin, cell surface marker expression or prolifération assays including thymidine incorporation.
These experiments are designed to validate compound adjuvant activity in different combinations of prime-boost schemes and assess how the effects of Kl N1000 or related compounds on the innate immune antiviral programs shape the adaptive immune responses mounted to the antigen in the vaccine préparations.
Detailed immune response analyses of each compound as described above are conducted with each selected antigen to détermine the immune correlates for that particular antigen(s) and compound formulation. These results guide the protection studies in which animais vaccinated and boosted with combinations of select optimized compounds and desired antigen(s) formulations from select infectious agents are later challenged with doses of infectious agent that are known to resuit in disease or death of the animal. Protection afforded by vaccination is typically measured by monitoring of clinical symptoms and survival.
A proof of concept experiment was performed. LEWIS female rats at 10-12 weeks of âge were primed with suspensions of antigen (ovalbumin, 0.2 mg/Kg) and KIN1000 (1 mg/Kg) or KIN1148 (1 mg/mL) in phosphate saline buffer (PBS) on day zéro. Control animais received ovalbumin (OVA, InvivoGen Inc.) in PBS or OVA with poly l:C (0.1 mg/Kg, InvivoGen Inc.). Animais were boosted at weeks 2, and 8. Vaccines were delivered subcutaneously in the footpad and base of the tail for priming and on the footpad and flank for the boosts (0.025 mL/site). Blood samples were collected by tail bleed and processed to sérum at 0, 1, 2, 4, 6, and 9 weeks post priming. Titers of OVA spécifie antibodies were determined by ELISA using anti IgM, anti IgG and anti IgG isotype spécifie antibodies. Figure 10 shows IgG antibody levels relative to OVA alone vaccinated Controls in OVA+KIN1000 and OVA+KIN1148 vaccinated animais.
Measurement of cell-mediated adjuvant activity is also determined by determining delayed type hypersensitivity (DTH) to an antigen. In the same proof of concept experiment, cellular responses were evaluated by determining the delayed type hypersensitivity reaction to challenge with OVA 2 weeks after the first boost. Animais were sedated with isoflurane and injected with PBS or OVA (0.02 mL of 1m/gmL solution of OVA in PBS) in the pinna of the left and right ears, respectively. 24 hours later the différence in ear thickness was calculated. Figure 11 shows measured différence between right ear and left ear thickness.
Unless otherwise indicated, ail numbers expressing quantities of ingrédients, properties such as molecular weight, reaction conditions, and so forth used in the spécification and daims are to be understood as being modified in ail instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the spécification and attached daims are approximations that can vary depending upon the desired properties sought to be obtained by the présent disclosure. At the very least, and not as an attempt to limit the application of the doctrine of équivalents to the scope of the daims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the disclosure are approximations, the numerical values set forth in the spécifie examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard déviation found in their respective testing measurements.
The terms “a,” “an,” “the” and similar referents used in the context of describing the disclosure (especially in the context of the following daims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring 41 individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the spécification as if it were individually recited herein. Ail methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and ail examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the disclosure and does not pose a limitation on the scope of the disclosure otherwise claimed. No language in the spécification should be construed as indicating any non-claimed element essential to the practice of the disclosure.
Groupings of alternative éléments or embodiments of the disclosure disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other éléments found herein. It is anticipated that one or more members of a group can be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or délétion occurs, the spécification is deemed to contain the group as modified thus fulfilling the written description of ail Markush groups used in the appended daims.
Certain embodiments of this disclosure are described herein, including the best mode known to the inventors for carrying out the disclosure. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the disclosure to be practiced otherwise than specifically described herein. Accordingly, this disclosure includes ail modifications and équivalents of the subject matter recited in the daims appended hereto as permitted by applicable law. Moreover, any combination of the above-described éléments in ail possible variations thereof is encompassed by the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.
Spécifie embodiments disclosed herein may be further limited in the daims using consisting of or and consisting essentially of language. When used in the daims, whether as filed or added per amendment, the transition term “consisting of’ excludes any element, step, or ingrédient not specified in the daims. The transition term “consisting essentially of” limits the scope of a daim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the disclosure so claimed are inherently or expressly described and enabled herein.
In closing, it is to be understood that the embodiments of the disclosure disclosed herein are illustrative of the principles of the présent disclosure. Other modifications that may be employed are within the scope of the disclosure. Thus, by way of example, but not of limitation, alternative configurations of the présent disclosure may be utilized in accordance with the teachings herein. Accordingly, the présent disclosure is not limited to that precisely as shown and described.
Claims (11)
1. A compound represented by the formula
wherein a dashed line indicates the presence or absence of a bond;
R1 is Ra, OR2 or NR2R3, optionally substituted naphthyl or substituted phenyl;
each Ra is independently H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted hydrocarbyl;
R2 and R3 are each independently Ra, CORa, or SO2Ra;
Y1, Y2, Y3 and Y4 are each independently CR4 or N, and optionally wherein Y1 and Y2 are both CR4 and together form an additional heterocyclic ring optionally substituted by R4;
each R4 is independently R2, ORa, NR2R3 SRa, SORa, SO2Ra, SO2NHRa, NCORa, halogen, trihalomethyl, CN, S=O, or nitro;
R5 is Ra, CORa, SO2Ra, optionally H or C4_3 alkyl, or is not présent;
V is C=O, CR2, CR2R3, COCR2R3, or C=NR2; and,
W and X are each independently S, O, N, NRa, CR2R4or CR4.
2. A compound of claim 1, further represented by a formula
wherein R10, R13, R14, R16, R17, R18, R19, R20, R21, and R22 are independently Rb, ORb, SRb, CORb, CO2Rb, OCORb, NRbRc, CONRbRc, NRbCORc, SO2NRbRc, CF3, CN, NO2, F, Cl, Br, I, or C2.5 heterocyclyl; each Rb is independently H or Cv3 hydrocarbyl, and each Rc is independently
H or Cv3 alkyl.
3. A compound of claim 1, wherein Y3 is CR4, wherein R4 is Rb, ORb, CORb, CO2Rb, OCORb, NRbRc, CF3, CN, NO2, F, Cl, Br, or I, wherein Rb and Rc are independently H or C^s alkyl, and/or wherein Y4 is CR4, wherein R4 is Rb, ORb, CORb, CO2Rb, OCORb, NRbRc, CF3, CN, NO2, F, Cl, Br, or I, wherein Rb and Rc are independently H or C-|.3 alkyl.
4. A compound of claim 1, further represented by the formula
wherein R10, Rn, R12, R13, Ru, Rw, R17, and Ri8 are independently Rb, ORb, CORb, CO2Rb, OCORb, NRbRc, CF3, CN, NO2, F, Cl, Br, or I, wherein Rb and Rc are independently H or C1.3 5 alkyl; and, R5 is H or Cv3 alkyl.
5 optionally, a vaccine against influenza virus, Hepatitis C virus, West Nile virus, SARScoronavirus, poliovirus, measles virus, Dengue virus, yellow fever virus, tick-borne encephalitis virus, Japanese encephalitis virus, St.
Louis encephalitis virus, Murray Valley virus, Powassan virus, Rocio virus, louping-ill virus, Banzi virus, llheus virus, Kokobera virus, Kunjin virus, Alfuy virus, bovine diarrhea virus, Kyasanur forest disease virus, respiratory syncytial virus or human 10 immunodeficiency virus (HIV).
5. A compound of claim 4, wherein R18 is CH3; and/or, wherein R13 is Br.
7. A pharmaceutical composition comprising a compound of any one of daims 1-6.
8. A compound of any one of daims 1-6, or a pharmaceutical composition of claim 7, for use in therapy.
5
9. A compound of any one of daims 1-6, or a pharmaceutical composition of claim 7, for the use in treating or preventing a viral infection in a vertebrate, the use comprising administering to the vertebrate a compound of any one of daims 1-6, or a pharmaceutical composition of claim 7;
optionally, wherein the viral infection is caused by a virus from one or more of the 10 following families: Arenaviridae, Astroviridae, Birnaviridae, Bromoviridae, Bunyaviridae, Caliciviridae, Closteroviridae, Comoviridae, Coronaviridae, Cystoviridae, Flaviviridae,
Flexiviridae, Hepevirus, Leviviridae, Luteoviridae, Mononegavirales, Mosaic Viruses, Nidovirales, Nodaviridae, Orthomyxoviridae, Picobirnavirus, Picornaviridae, Potyviridae, Reoviridae, Retroviridae, Sequiviridae, Tenuivirus, Togaviridae, Tombusviridae, Totiviridae, 15 Tymoviridae, Hepadnaviridae, Herpesviridae, Paramyxoviridae or Papillomaviridae;
optionally, wherein the viral infection is influenza virus, Hepatitis C virus, West Nile virus, SARS-coronavirus, poliovirus, measles virus, Dengue virus, yellow fever virus, tick-borne encephalitis virus, Japanese encephalitis virus, St. Louis encephalitis virus, Murray Valley virus, Powassan virus, Rocio virus, louping-ill virus, Banzi virus, llheus virus, Kokobera virus, Kunjin virus, Alfuy virus, bovine diarrhea virus, Kyasanur forest disease virus, respiratory syncytial virus or human immunodeficiency virus (HIV).
10. A compound of any one of daims 1-6, or a pharmaceutical composition of claim 7, for use as an adjuvant for a prophylactic or therapeutic vaccine;
11. A compound of any one of daims 1-6 for use in modulating the innate immune response in a eukaryotic cell, the use comprising administering to the cell a compound of any one of daims 1-6, optionally wherein the cell is in vivo or in vitro.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/542,049 | 2011-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19256A true OA19256A (en) | 2020-06-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200270274A1 (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | |
US20160102099A1 (en) | Anti-viral compounds | |
AU2017254812B2 (en) | Anti-viral compounds | |
AU2014290108A1 (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | |
WO2016073947A1 (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | |
US20150342932A1 (en) | Anti-viral compounds | |
OA19256A (en) | Anti-Viral Compounds. | |
JP2013525365A (en) | Antiviral compounds | |
NZ622636B2 (en) | Substituted benzothiazole compounds and their use in the treatment of viral infections |